ZA200209904B - Novel compounds. - Google Patents
Novel compounds. Download PDFInfo
- Publication number
- ZA200209904B ZA200209904B ZA200209904A ZA200209904A ZA200209904B ZA 200209904 B ZA200209904 B ZA 200209904B ZA 200209904 A ZA200209904 A ZA 200209904A ZA 200209904 A ZA200209904 A ZA 200209904A ZA 200209904 B ZA200209904 B ZA 200209904B
- Authority
- ZA
- South Africa
- Prior art keywords
- phenyl
- compound
- formula
- acetamide
- hydroxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 102
- -1 nitro, carboxyl Chemical group 0.000 claims description 71
- 125000000217 alkyl group Chemical group 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 47
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 41
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 40
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 40
- 239000012453 solvate Substances 0.000 claims description 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 39
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 32
- 229910052799 carbon Inorganic materials 0.000 claims description 29
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 24
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims description 20
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 15
- 229920006395 saturated elastomer Polymers 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 125000004414 alkyl thio group Chemical group 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 208000006673 asthma Diseases 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 6
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 239000005864 Sulphur Chemical group 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 102000009410 Chemokine receptor Human genes 0.000 claims description 4
- 108050000299 Chemokine receptor Proteins 0.000 claims description 4
- 229910052792 caesium Inorganic materials 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- ZWHVZEVXTBVHKA-UHFFFAOYSA-N 2-[3-[[1-[(4-fluorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1OCC(O)CNC1CCN(CC=2C=CC(F)=CC=2)CC1 ZWHVZEVXTBVHKA-UHFFFAOYSA-N 0.000 claims description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 3
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- OVJRIIXZEYSYCL-UHFFFAOYSA-N n-[2-[3-[[1-[(3,4-dichlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxy-2-methylpropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(C)(O)CNC1CCN(CC=2C=C(Cl)C(Cl)=CC=2)CC1 OVJRIIXZEYSYCL-UHFFFAOYSA-N 0.000 claims description 3
- ROYXRRXTBDPMIB-UHFFFAOYSA-N n-[2-[3-[[1-[(3-chloro-4-fluorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(O)CNC1CCN(CC=2C=C(Cl)C(F)=CC=2)CC1 ROYXRRXTBDPMIB-UHFFFAOYSA-N 0.000 claims description 3
- ZHFGLTBMIUEXKD-UHFFFAOYSA-N n-[2-[3-[[1-[(3-chloro-4-fluorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]phenyl]benzamide Chemical compound C=1C=CC=C(NC(=O)C=2C=CC=CC=2)C=1OCC(O)CNC(CC1)CCN1CC1=CC=C(F)C(Cl)=C1 ZHFGLTBMIUEXKD-UHFFFAOYSA-N 0.000 claims description 3
- JNJDANVEPOEXLR-UHFFFAOYSA-N n-[2-[3-[[1-[(3-chlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]phenyl]-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound N1C(C)=CC(C)=C1C(=O)NC1=CC=CC=C1OCC(O)CNC1CCN(CC=2C=C(Cl)C=CC=2)CC1 JNJDANVEPOEXLR-UHFFFAOYSA-N 0.000 claims description 3
- GIEYOQOEWUNJGM-UHFFFAOYSA-N n-[2-[3-[[1-[(4-bromophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]phenyl]-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound N1C(C)=CC(C)=C1C(=O)NC1=CC=CC=C1OCC(O)CNC1CCN(CC=2C=CC(Br)=CC=2)CC1 GIEYOQOEWUNJGM-UHFFFAOYSA-N 0.000 claims description 3
- FYQVZTPVNNFPST-UHFFFAOYSA-N n-[2-[3-[[1-[(4-chlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-6-fluorophenyl]acetamide Chemical compound CC(=O)NC1=C(F)C=CC=C1OCC(O)CNC1CCN(CC=2C=CC(Cl)=CC=2)CC1 FYQVZTPVNNFPST-UHFFFAOYSA-N 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- LSBDFXRDZJMBSC-UHFFFAOYSA-N Amide-Phenylacetic acid Natural products NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- UHWWMQGKINJTML-XMMPIXPASA-N n-[2-[(2r)-3-[[1-[(4-chlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxy-2-methylpropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OC[C@](C)(O)CNC1CCN(CC=2C=CC(Cl)=CC=2)CC1 UHWWMQGKINJTML-XMMPIXPASA-N 0.000 claims description 2
- LYQPXPOTVRGEDB-UHFFFAOYSA-N n-[2-[3-[[1-[(4-bromophenyl)methyl]piperidin-4-yl]amino]-2-hydroxy-2-methylpropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(C)(O)CNC1CCN(CC=2C=CC(Br)=CC=2)CC1 LYQPXPOTVRGEDB-UHFFFAOYSA-N 0.000 claims description 2
- NCRZBMXHPCBDHQ-UHFFFAOYSA-N n-[2-[3-[[1-[(4-bromophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(O)CNC1CCN(CC=2C=CC(Br)=CC=2)CC1 NCRZBMXHPCBDHQ-UHFFFAOYSA-N 0.000 claims description 2
- VKAWDNYVQDHWLT-UHFFFAOYSA-N n-[2-[3-[[1-[(4-chlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxy-2-methylpropoxy]phenyl]benzamide Chemical compound C=1C=CC=C(NC(=O)C=2C=CC=CC=2)C=1OCC(O)(C)CNC(CC1)CCN1CC1=CC=C(Cl)C=C1 VKAWDNYVQDHWLT-UHFFFAOYSA-N 0.000 claims description 2
- JREWIIXZKFBBRF-UHFFFAOYSA-N n-[2-[3-[[1-[(4-fluorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(O)CNC1CCN(CC=2C=CC(F)=CC=2)CC1 JREWIIXZKFBBRF-UHFFFAOYSA-N 0.000 claims description 2
- XBGPOFSOBGESNM-NRFANRHFSA-N n-[4-fluoro-2-[(2s)-3-[[1-[(4-fluorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=C(F)C=C1OC[C@@H](O)CNC1CCN(CC=2C=CC(F)=CC=2)CC1 XBGPOFSOBGESNM-NRFANRHFSA-N 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 23
- 230000009286 beneficial effect Effects 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- XZZCEIOLUHBWLL-NRFANRHFSA-N n-[2-[(2s)-3-[[1-[(4-chlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-4-fluorophenyl]acetamide Chemical compound CC(=O)NC1=CC=C(F)C=C1OC[C@@H](O)CNC1CCN(CC=2C=CC(Cl)=CC=2)CC1 XZZCEIOLUHBWLL-NRFANRHFSA-N 0.000 claims 1
- FBMVIPOJAIEMEQ-UHFFFAOYSA-N n-[2-[3-[[1-[(3,4-dichlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-4-fluorophenyl]acetamide Chemical compound CC(=O)NC1=CC=C(F)C=C1OCC(O)CNC1CCN(CC=2C=C(Cl)C(Cl)=CC=2)CC1 FBMVIPOJAIEMEQ-UHFFFAOYSA-N 0.000 claims 1
- DQKWBTYEFDDBCD-UHFFFAOYSA-N n-[2-[3-[[1-[(3,4-dichlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]phenyl]benzamide Chemical compound C=1C=CC=C(NC(=O)C=2C=CC=CC=2)C=1OCC(O)CNC(CC1)CCN1CC1=CC=C(Cl)C(Cl)=C1 DQKWBTYEFDDBCD-UHFFFAOYSA-N 0.000 claims 1
- MBQWSRZWBXESPI-UHFFFAOYSA-N n-[2-[3-[[1-[(3,4-difluorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxy-2-methylpropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(C)(O)CNC1CCN(CC=2C=C(F)C(F)=CC=2)CC1 MBQWSRZWBXESPI-UHFFFAOYSA-N 0.000 claims 1
- XVXUQBGLPUEGPD-UHFFFAOYSA-N n-[2-[3-[[1-[(3,4-difluorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(O)CNC1CCN(CC=2C=C(F)C(F)=CC=2)CC1 XVXUQBGLPUEGPD-UHFFFAOYSA-N 0.000 claims 1
- XXJAJULFILCYBG-UHFFFAOYSA-N n-[2-[3-[[1-[(3-fluorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]phenyl]-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound N1C(C)=CC(C)=C1C(=O)NC1=CC=CC=C1OCC(O)CNC1CCN(CC=2C=C(F)C=CC=2)CC1 XXJAJULFILCYBG-UHFFFAOYSA-N 0.000 claims 1
- UHWWMQGKINJTML-UHFFFAOYSA-N n-[2-[3-[[1-[(4-chlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxy-2-methylpropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(C)(O)CNC1CCN(CC=2C=CC(Cl)=CC=2)CC1 UHWWMQGKINJTML-UHFFFAOYSA-N 0.000 claims 1
- IIOAUCXGBIQVDS-UHFFFAOYSA-N n-[3-acetyl-2-[3-[[1-[(3,4-dichlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-5-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C)=CC(C(C)=O)=C1OCC(O)CNC1CCN(CC=2C=C(Cl)C(Cl)=CC=2)CC1 IIOAUCXGBIQVDS-UHFFFAOYSA-N 0.000 claims 1
- YILMPRHXSAYTAZ-UHFFFAOYSA-N n-[4-fluoro-2-[3-[[1-[(4-fluorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxy-2-methylpropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=C(F)C=C1OCC(C)(O)CNC1CCN(CC=2C=CC(F)=CC=2)CC1 YILMPRHXSAYTAZ-UHFFFAOYSA-N 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 83
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 52
- 239000000243 solution Substances 0.000 description 44
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 235000019439 ethyl acetate Nutrition 0.000 description 20
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 20
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 18
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 17
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 17
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 17
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 17
- 150000002118 epoxides Chemical class 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- 229940093499 ethyl acetate Drugs 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 11
- 206010039083 rhinitis Diseases 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 8
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- XQGVQRPSTODODM-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrrole-2-carboxylic acid Chemical compound CC1=CC(C)=C(C(O)=O)N1 XQGVQRPSTODODM-UHFFFAOYSA-N 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 7
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000035605 chemotaxis Effects 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 108010004073 cysteinylcysteine Proteins 0.000 description 4
- 125000006606 n-butoxy group Chemical group 0.000 description 4
- 125000006252 n-propylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002975 chemoattractant Substances 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 3
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- MCGIQVVVGVAMEI-UHFFFAOYSA-N 1-[(3,4-dichlorophenyl)methyl]piperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=C(Cl)C(Cl)=C1 MCGIQVVVGVAMEI-UHFFFAOYSA-N 0.000 description 2
- BIMZLZOTBSPLRM-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]piperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=C(Cl)C=C1 BIMZLZOTBSPLRM-UHFFFAOYSA-N 0.000 description 2
- ADVGKWPZRIDURE-UHFFFAOYSA-N 2'-Hydroxyacetanilide Chemical compound CC(=O)NC1=CC=CC=C1O ADVGKWPZRIDURE-UHFFFAOYSA-N 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- JYNYZGTZSYGZFF-UHFFFAOYSA-N 2-[3-[[1-[(4-bromophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1OCC(O)CNC1CCN(CC=2C=CC(Br)=CC=2)CC1 JYNYZGTZSYGZFF-UHFFFAOYSA-N 0.000 description 2
- OSBDKNMYPCZPAJ-UHFFFAOYSA-N 2-[3-[[1-[(4-chlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1OCC(O)CNC1CCN(CC=2C=CC(Cl)=CC=2)CC1 OSBDKNMYPCZPAJ-UHFFFAOYSA-N 0.000 description 2
- QOZLOYKAFDTQNU-UHFFFAOYSA-N 2-amino-3-fluorophenol Chemical compound NC1=C(O)C=CC=C1F QOZLOYKAFDTQNU-UHFFFAOYSA-N 0.000 description 2
- BCKXMQIYWWTZDP-UHFFFAOYSA-N 2-hydroxy-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1O BCKXMQIYWWTZDP-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 101100366940 Mus musculus Stom gene Proteins 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 102100036154 Platelet basic protein Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- YITODUZHQFVOEZ-LLVKDONJSA-N [(2r)-2-methyloxiran-2-yl]methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC[C@]1(C)OC1 YITODUZHQFVOEZ-LLVKDONJSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- WFKAJVHLWXSISD-UHFFFAOYSA-N anhydrous dimethyl-acetamide Natural products CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 108010035886 connective tissue-activating peptide Proteins 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 229940047889 isobutyramide Drugs 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- WWQLYMAILGXGDX-UHFFFAOYSA-N n-(2-fluoro-6-hydroxyphenyl)acetamide Chemical compound CC(=O)NC1=C(O)C=CC=C1F WWQLYMAILGXGDX-UHFFFAOYSA-N 0.000 description 2
- UYKVWAQEMQDRGG-UHFFFAOYSA-N n-(2-hydroxyphenyl)benzamide Chemical compound OC1=CC=CC=C1NC(=O)C1=CC=CC=C1 UYKVWAQEMQDRGG-UHFFFAOYSA-N 0.000 description 2
- XPODWBQYZVBKMF-UHFFFAOYSA-N n-[2-(oxiran-2-ylmethoxy)phenyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NC1=CC=CC=C1OCC1CO1 XPODWBQYZVBKMF-UHFFFAOYSA-N 0.000 description 2
- ASMACUZVQOCUAE-UHFFFAOYSA-N n-[2-[(2-methyloxiran-2-yl)methoxy]phenyl]benzamide Chemical compound C=1C=CC=C(NC(=O)C=2C=CC=CC=2)C=1OCC1(C)CO1 ASMACUZVQOCUAE-UHFFFAOYSA-N 0.000 description 2
- SFSYBIMGDOACAY-UHFFFAOYSA-N n-[2-[3-[[1-[(3,4-dichlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-5-fluorophenyl]acetamide Chemical compound CC(=O)NC1=CC(F)=CC=C1OCC(O)CNC1CCN(CC=2C=C(Cl)C(Cl)=CC=2)CC1 SFSYBIMGDOACAY-UHFFFAOYSA-N 0.000 description 2
- MNBLPGMJPDFOBA-UHFFFAOYSA-N n-[2-[3-[[1-[(3,4-difluorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]phenyl]benzamide Chemical compound C=1C=CC=C(NC(=O)C=2C=CC=CC=2)C=1OCC(O)CNC(CC1)CCN1CC1=CC=C(F)C(F)=C1 MNBLPGMJPDFOBA-UHFFFAOYSA-N 0.000 description 2
- NACXBKZWHYBDEL-UHFFFAOYSA-N n-[2-[3-[[1-[(3-chloro-4-fluorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxy-2-methylpropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(C)(O)CNC1CCN(CC=2C=C(Cl)C(F)=CC=2)CC1 NACXBKZWHYBDEL-UHFFFAOYSA-N 0.000 description 2
- BEDLBOVTEKQZCR-UHFFFAOYSA-N n-[2-[3-[[1-[(4-chlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-4-methoxyphenyl]acetamide Chemical compound COC1=CC=C(NC(C)=O)C(OCC(O)CNC2CCN(CC=3C=CC(Cl)=CC=3)CC2)=C1 BEDLBOVTEKQZCR-UHFFFAOYSA-N 0.000 description 2
- KPPHYQMDMZRERL-UHFFFAOYSA-N n-[2-[3-[[1-[(4-fluorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-6-methylphenyl]acetamide Chemical compound CC(=O)NC1=C(C)C=CC=C1OCC(O)CNC1CCN(CC=2C=CC(F)=CC=2)CC1 KPPHYQMDMZRERL-UHFFFAOYSA-N 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- ODNFVADIRXKBCY-UHFFFAOYSA-N pyrrolidin-1-yl carbamate Chemical compound NC(=O)ON1CCCC1 ODNFVADIRXKBCY-UHFFFAOYSA-N 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical class [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AAVHHYWBSVSPPN-UHFFFAOYSA-N (2-methyloxiran-2-yl)methanol Chemical compound OCC1(C)CO1 AAVHHYWBSVSPPN-UHFFFAOYSA-N 0.000 description 1
- SMKKEOQDQNCTGL-ZETCQYMHSA-N (2s)-2-[(2-nitrophenoxy)methyl]oxirane Chemical compound [O-][N+](=O)C1=CC=CC=C1OC[C@H]1OC1 SMKKEOQDQNCTGL-ZETCQYMHSA-N 0.000 description 1
- GLXIMRGOPABCGC-LLVKDONJSA-N (3r)-1-[(4-chlorophenyl)methyl]pyrrolidin-3-amine Chemical compound C1[C@H](N)CCN1CC1=CC=C(Cl)C=C1 GLXIMRGOPABCGC-LLVKDONJSA-N 0.000 description 1
- NBIOUVFLTIZZER-UHFFFAOYSA-N 1,2-dichloro-4-(chloromethyl)benzene;1-[(3,4-dichlorophenyl)methyl]piperidin-4-amine Chemical compound ClCC1=CC=C(Cl)C(Cl)=C1.C1CC(N)CCN1CC1=CC=C(Cl)C(Cl)=C1 NBIOUVFLTIZZER-UHFFFAOYSA-N 0.000 description 1
- SSNCMIDZGFCTST-UHFFFAOYSA-N 1,3-difluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=C(F)C=CC=C1F SSNCMIDZGFCTST-UHFFFAOYSA-N 0.000 description 1
- WNQXIWMYWRHSNU-UHFFFAOYSA-N 1-[(3,4-difluorophenyl)methyl]piperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=C(F)C(F)=C1 WNQXIWMYWRHSNU-UHFFFAOYSA-N 0.000 description 1
- ALGMTGVLDUQQSJ-UHFFFAOYSA-N 1-[(3-chloro-4-fluorophenyl)methyl]piperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=C(F)C(Cl)=C1 ALGMTGVLDUQQSJ-UHFFFAOYSA-N 0.000 description 1
- DDPNUBVUABSUEG-UHFFFAOYSA-N 1-[(4-bromophenyl)methyl]piperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=C(Br)C=C1 DDPNUBVUABSUEG-UHFFFAOYSA-N 0.000 description 1
- DCEXCMVFRCTUOL-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]piperidine Chemical compound C1=CC(Cl)=CC=C1CN1CCCCC1 DCEXCMVFRCTUOL-UHFFFAOYSA-N 0.000 description 1
- KRIHULMCWJRKQE-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=C(F)C=C1 KRIHULMCWJRKQE-UHFFFAOYSA-N 0.000 description 1
- YUBDLZGUSSWQSS-UHFFFAOYSA-N 1-benzylpiperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=C1 YUBDLZGUSSWQSS-UHFFFAOYSA-N 0.000 description 1
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 1
- VVHFXJOCUKBZFS-UHFFFAOYSA-N 2-(chloromethyl)-2-methyloxirane Chemical compound ClCC1(C)CO1 VVHFXJOCUKBZFS-UHFFFAOYSA-N 0.000 description 1
- PTHRRXYZMDTTOA-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)phenyl]acetamide Chemical compound NC(=O)CC1=CC=CC=C1OCC1OC1 PTHRRXYZMDTTOA-UHFFFAOYSA-N 0.000 description 1
- CNEBJKQGOODBFD-UHFFFAOYSA-N 2-[3-[[1-[(3,4-dichlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1OCC(O)CNC1CCN(CC=2C=C(Cl)C(Cl)=CC=2)CC1 CNEBJKQGOODBFD-UHFFFAOYSA-N 0.000 description 1
- FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000027445 Farmer Lung Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 1
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 208000009388 Job Syndrome Diseases 0.000 description 1
- 206010024227 Lepromatous leprosy Diseases 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047112 Vasculitides Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- XEBCWEDRGPSHQH-YUMQZZPRSA-N dipropan-2-yl (2s,3s)-2,3-dihydroxybutanedioate Chemical compound CC(C)OC(=O)[C@@H](O)[C@H](O)C(=O)OC(C)C XEBCWEDRGPSHQH-YUMQZZPRSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- IZSBSZYFPYIJDI-UHFFFAOYSA-N ethyl 3,5-dimethyl-1h-pyrrole-2-carboxylate Chemical compound CCOC(=O)C=1NC(C)=CC=1C IZSBSZYFPYIJDI-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000022195 farmer lung disease Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010051040 hyper-IgE syndrome Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- PHOAIOPTKPVQOB-UHFFFAOYSA-N n-(2-hydroxy-4-methoxyphenyl)acetamide Chemical compound COC1=CC=C(NC(C)=O)C(O)=C1 PHOAIOPTKPVQOB-UHFFFAOYSA-N 0.000 description 1
- HTVPAACTHAQQAS-UHFFFAOYSA-N n-(2-hydroxy-4-methylphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(C)C=C1O HTVPAACTHAQQAS-UHFFFAOYSA-N 0.000 description 1
- NEOWELJZRVSZFJ-UHFFFAOYSA-N n-(2-hydroxy-6-methylphenyl)acetamide Chemical compound CC(=O)NC1=C(C)C=CC=C1O NEOWELJZRVSZFJ-UHFFFAOYSA-N 0.000 description 1
- SENIMHNFLVMDJV-UHFFFAOYSA-N n-[2-(oxiran-2-ylmethoxy)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC1OC1 SENIMHNFLVMDJV-UHFFFAOYSA-N 0.000 description 1
- UHWWMQGKINJTML-DEOSSOPVSA-N n-[2-[(2s)-3-[[1-[(4-chlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxy-2-methylpropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OC[C@@](C)(O)CNC1CCN(CC=2C=CC(Cl)=CC=2)CC1 UHWWMQGKINJTML-DEOSSOPVSA-N 0.000 description 1
- XZZZCTNRNINFIV-NRFANRHFSA-N n-[2-[(2s)-3-[[1-[(4-chlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OC[C@@H](O)CNC1CCN(CC=2C=CC(Cl)=CC=2)CC1 XZZZCTNRNINFIV-NRFANRHFSA-N 0.000 description 1
- VCFZUDKMHJJFCH-UHFFFAOYSA-N n-[2-[3-[[1-[(3,4-dichlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-5-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C)=CC=C1OCC(O)CNC1CCN(CC=2C=C(Cl)C(Cl)=CC=2)CC1 VCFZUDKMHJJFCH-UHFFFAOYSA-N 0.000 description 1
- RZZMEDRZZKDEKU-UHFFFAOYSA-N n-[2-[3-[[1-[(3,4-dichlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-6-methylphenyl]acetamide Chemical compound CC(=O)NC1=C(C)C=CC=C1OCC(O)CNC1CCN(CC=2C=C(Cl)C(Cl)=CC=2)CC1 RZZMEDRZZKDEKU-UHFFFAOYSA-N 0.000 description 1
- CYSCAVXFUNWUFH-UHFFFAOYSA-N n-[2-[3-[[1-[(4-bromophenyl)methyl]piperidin-4-yl]amino]-2-hydroxy-2-methylpropoxy]phenyl]benzamide Chemical compound C=1C=CC=C(NC(=O)C=2C=CC=CC=2)C=1OCC(O)(C)CNC(CC1)CCN1CC1=CC=C(Br)C=C1 CYSCAVXFUNWUFH-UHFFFAOYSA-N 0.000 description 1
- XZZCEIOLUHBWLL-UHFFFAOYSA-N n-[2-[3-[[1-[(4-chlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-4-fluorophenyl]acetamide Chemical compound CC(=O)NC1=CC=C(F)C=C1OCC(O)CNC1CCN(CC=2C=CC(Cl)=CC=2)CC1 XZZCEIOLUHBWLL-UHFFFAOYSA-N 0.000 description 1
- YWCRNYCJOLGBBS-UHFFFAOYSA-N n-[2-[3-[[1-[(4-chlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-5-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC(C)=CC=C1OCC(O)CNC1CCN(CC=2C=CC(Cl)=CC=2)CC1 YWCRNYCJOLGBBS-UHFFFAOYSA-N 0.000 description 1
- OTSQSUHXXKRRPY-UHFFFAOYSA-N n-[2-[3-[[1-[(4-chlorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]phenyl]benzamide Chemical compound C=1C=CC=C(NC(=O)C=2C=CC=CC=2)C=1OCC(O)CNC(CC1)CCN1CC1=CC=C(Cl)C=C1 OTSQSUHXXKRRPY-UHFFFAOYSA-N 0.000 description 1
- JHINGSHMHAREOG-UHFFFAOYSA-N n-[2-[3-[[1-[(4-fluorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxy-2-methylpropoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1OCC(C)(O)CNC1CCN(CC=2C=CC(F)=CC=2)CC1 JHINGSHMHAREOG-UHFFFAOYSA-N 0.000 description 1
- AKFLRPNJJJZUED-UHFFFAOYSA-N n-[2-[3-[[1-[(4-fluorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxy-2-methylpropoxy]phenyl]benzamide Chemical compound C=1C=CC=C(NC(=O)C=2C=CC=CC=2)C=1OCC(O)(C)CNC(CC1)CCN1CC1=CC=C(F)C=C1 AKFLRPNJJJZUED-UHFFFAOYSA-N 0.000 description 1
- HNRGYRDDEBEHOH-UHFFFAOYSA-N n-[2-[3-[[1-[(4-fluorophenyl)methyl]piperidin-4-yl]amino]-2-hydroxypropoxy]-4-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C)C=C1OCC(O)CNC1CCN(CC=2C=CC(F)=CC=2)CC1 HNRGYRDDEBEHOH-UHFFFAOYSA-N 0.000 description 1
- OQZXFSZBCFKHMX-UHFFFAOYSA-N n-[2-fluoro-6-(oxiran-2-ylmethoxy)phenyl]acetamide Chemical compound CC(=O)NC1=C(F)C=CC=C1OCC1OC1 OQZXFSZBCFKHMX-UHFFFAOYSA-N 0.000 description 1
- ATQSLKHGSWFGIB-UHFFFAOYSA-N n-[4-methoxy-2-(oxiran-2-ylmethoxy)phenyl]acetamide Chemical compound COC1=CC=C(NC(C)=O)C(OCC2OC2)=C1 ATQSLKHGSWFGIB-UHFFFAOYSA-N 0.000 description 1
- IYQNZAROPVZDKE-UHFFFAOYSA-N n-[4-methyl-2-(oxiran-2-ylmethoxy)phenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C)C=C1OCC1OC1 IYQNZAROPVZDKE-UHFFFAOYSA-N 0.000 description 1
- XYNZOQAPGUNBDC-UHFFFAOYSA-N n-methyl-2-(oxiran-2-ylmethoxy)benzamide Chemical compound CNC(=O)C1=CC=CC=C1OCC1OC1 XYNZOQAPGUNBDC-UHFFFAOYSA-N 0.000 description 1
- VBWWRHGQADUAFE-UHFFFAOYSA-N n-methyl-2-[(2-methyloxiran-2-yl)methoxy]benzamide Chemical compound CNC(=O)C1=CC=CC=C1OCC1(C)OC1 VBWWRHGQADUAFE-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JHYOUOHNCPGQOS-UHFFFAOYSA-N tert-butyl 3-hydroxypiperidine-1-carboxylate;3-(4-chlorophenoxy)piperidine Chemical compound CC(C)(C)OC(=O)N1CCCC(O)C1.C1=CC(Cl)=CC=C1OC1CNCCC1 JHYOUOHNCPGQOS-UHFFFAOYSA-N 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 201000005539 vernal conjunctivitis Diseases 0.000 description 1
Landscapes
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
‘ \
NOVEL COMPOUNDS
The present invention relates to novel compounds, processes for their preparation, . pharmaceutical compositions containing them and their use in therapy.
Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) and Cys-Cys (C-C) families. These are distinguished on the basis of a single amino acid insertion between the
NH-proximal pair of cysteine residues and sequence similarity.
The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).
The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and
MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1a and 1p (MIP-1o and MIP-1p). . Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2,
CCR2A, CCR2B, CCR3, CCR4, CCRS, CCR6, CCR7, CCR8, CCRY, CCR10, CXCRI, . CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug - development since agents which modulate these receptors would be useful in the treatment ’ of disorders and diseases such as those mentioned above.
‘ )
In accordance with the present invention, there is therefore provided a compound of general formula
RL NT R 5 R J
NG Pd SON) ~< AR
SE on a son ~ @ s wherein mis 0, 1,2o0r3; each R' independently represents halogen, cyano, nitro, carboxyl, hydroxyl,
C3-Cg cycloalkyl, C;-Cg alkoxy, C;-Cq alkoxycarbonyl, C,-Cg4 haloalkyl,
C-Cg¢ haloalkoxy, NERY, C;3-Cg cycloalkylamino, C;-C alkylthio, 10 C;-Cg alkylcarbonyl, C;-Cgq alkylcarbonylamino, sulphonamido (-SO,NH,),
C,-Cg alkylsulphonyl, -C(O)NR''R'?, -NR"C(0)-(NH),R", phenyl, or C;-Cq alkyl optionally substituted by carboxyi or C;-Cg alkoxycarbonyi; pisUorl;
Zz! represents a bond or a group (CH,), where q is 1 or 2; 7? represents a bond or a group CH,, with the proviso that 7! and Z* do not both simultaneously represent a bond;
Q represents an oxygen or sulphur atom or a group CH, or NH;
R? represents a group
RY
Ten nis 0,1 or2; ‘ each R independently represents a C-Cg alkyl, C;-C¢ alkoxycarbonyl, -CH,OH or - carboxyl group;
RY, R’, R® and R” each independently represent a hydrogen atom or a C;-Cg alkyl group, Or R?, Rr, R® and R’ together represent a C|-C, alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle, or R’, R® and R” each represent a hydrogen atom and R* and R® together with the carbon atoms to which they are attached form a 5- to 6-membered saturated carbocycle; , r® represents a hydrogen atom, a Cy-Cg alkyl group or is linked to R* as defined s above;
R® and R' each independently represent a hydrogen atom or a C;-Cg alkyl group, or
R’ and rR" together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
R'! and R'? each independently represent a hydrogen atom or a C;-Cg alkyl group to optionally substituted by C;-C¢ alkoxycarbonyl; rR" represents a hydrogen stom or a C;-Cg alkyl group; rR" represents a hydrogen atom, or a C;-Cg¢ alkyl group optionally substituted by carboxyl, C,-Cg alkoxy or C,-C¢ alkoxycarbonyl;
RY represents carboxyl, C;-Cg4 alkoxy, C,-Cg alkylcarbonyl, C;-Cg4 alkoxycarbonyl, 1s C;-Cg alkoxycarbonylC,-Cg alkyl ora group -NR''R'®, -NIISO,CH;, -C(ONR''R"S,
NHC(O)NR'"R'®, -0C(O)NR''R'®, -OCH,C(O)NR''R'®, -NHC(O)OR' or
NHC(O)R*’; tis 0,1, 2 or 3; each R!® independently represents halogen, cyano, nitro, carboxyl, hydroxyl,
C3-Cg cycloalkyl, C,-Cg alkoxy, C;-Cg4 alkoxycarbonyl, C,-Cg4 haloalkyl,
C,-Cg haloalkoxy, -NR*'R*?, C3-C¢ cycloalkylamino, C,-Cj alkylthio,
C,-Cg alkylcarbonyl, C-Cq alkylcarbonylamino, sulphonamido (-SO,NH,),
C,-Cg alkylsulphonyl, -C(O)NRZR**, -NR*C(O)(NH),R?S, phenyl, or C;-C; alkyl optionally substituted by carboxyl or C;-Cg4 alkoxycarbonyl;
R'” and R'® each independently represent a hydrogen atom, or a C,-Cg alkyl group . optionally substituted by carboxyl or C,-Cg4 alkoxycarbonyl, or R!7 and R"® together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated ’ heterocycle; rR" represents a hydrogen atom, or a C;-Cg alkyl group optionally substituted by carboxyl or C;-Cg4 alkoxycarbonyl,
/ N
RY represents a group C-Cq alkyl, C,-Cq alkenyl, C;3-Cq cycloalkyl, adamantyl,
Cs5-Cg cycloalkenyl, phenyl or a saturated or unsaturated 5- to 10-membered heterocyclic ring system comprising at least one heteroatom selected from nitrogen, oxygen and sulphur, each of which may be optionally substituted by one or more substituents ‘ independently selected from nitro, hydroxyl, oxo, halogen, carboxyl, C;-C alkyl,
Ci-Cg alkoxy, C,-Cg alkylthio, C-Cg alkylcarbonyl, C-C, alkoxycarbonyl, phenyl! and _NHC(0)-R*’;
R*' and R** each independently represent a hydrogen atom or a C;-Cyg alkyl group, or
R*! and R* together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
R™ and R* each independently represent a hydrogen atom or a C-Cg alkyl group optionally substituted by C,-Cg alkoxycarbonyl; visOor 1; n> represents a hydrogen atom or 2 C=C alkyl aroun:
R% represents a hydrogen atom. or a C;-Cg alkyl group optionally substituted by carboxyl, C,-Cq alkoxy or C;-C alkoxycarbonyl; and
RY’ represents a C,-Cg alkyl, amino (-NH,) or phenyl group; or a pharmaceutically acceptable salt or solvate thereof.
In the context of the present specification, an alkyl substituent group or an alkyl moiety in a substituent group may be linear or branched. When R’ and R'° (or R' and R'E, or R*! and R%) represent a saturated heterocycle, it should be understood that the only heteroatom present is the nitrogen atom to which R’ and R'? (or R'7 and R'E, or R? and rR) are attached. In the definition of rR, it should be noted that the saturated or unsaturated 5- to 2s 10-membered heterocyclic ring system may be aliphatic or aromatic.
The integer m is preferably 1 or 2.
Each R' independently represents halogen (e.g. chlorine, fluorine, bromine or iodine), cyano, nitro, carboxyl, hydroxyl, C;-C¢ cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), C;-Cg, preferably C;-C,, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C,-Cg, preferably C,-C,, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), C;-Cg, preferably C;-Cy, haloalkyl (e.g. trifluoromethyl), . C,-Cg, preferably C,-C,, haloalkoxy (e.g. trifluoromethoxy), NR°R'?, 5s C3-Cg cycloalkylamino (e.g. cyclopropylamino, cyclobutylamino, cyclopentylamino or cyclohexylamino), C;-Cg, preferably C;-C,, alkylthio (e.g. methylthio or ethylthio),
C,-Cq, preferably C,-C,, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), C,-Cg, preferably C;-C,, alkylcarbonylamino (e.g. methylcarbonylamino or ethylcarbonylamino), sulphonamido,
C.-C, preferably C;-C,, alkylsulphonyl (e.g. methylsulphonyl, ethylsulphonyl, n-propylsulphonyl, isopropylsulphonyl, n-butylsulphonyl, n-pentylsulphonyl or n-hexylsulphonyl), -C(O)NR''R'%, -NR"C(0)-(NH),R", phenyl, or
C,-C, preferably C;-C,, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl or C;-Cg, preferably
C,-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl).
Most preferably, each R' independently represents halogen (particularly chlorine or fluorine), cyano, nitro, C;-Cg alkoxy (especially methoxy), C;-Cg alkylcarbonyl (especially methylcarbonyl) or C,-Cg alkylcarbonylamino (particularly methylcarbonylamino). Each R' especially represents a halogen atom.
Q preferably represents an oxygen atom. 2» EachR’ independently represents a C;-Cg, preferably C,-Cy, alkyl (e.g. methyl, ethyl, . n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-penty! or n-hexyl), C,-C, preferably
C,-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), -CH,OH or carboxyl group. It is preferred that rR’ represents a methyl, methoxycarbonyl, ethoxycarbonyl, -CH,OH or carboxy! group.
RY, R’, R® and R” each independently represent a hydrogen atom or a C,-Cg, preferably
C,-Cy, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), or RY, Rr’, Rand R’ together represent a C;-C, alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle ‘ s {e.g cyclohexyl! or preferably cyclopentyl), or R’, R® and R7 each represent a hydrogen atom and R” and R® together with the carbon atoms tc which they are attached form a 5- to 6-membered saturated carbocycle (preferably cyclopentyl).
R® represents a hydrogen atom, a Cy-Cg, preferably C,-Cy, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) or is linked to R* as defined above.
R® and R'? each independently represent a hydrogen atom or a C,-Cg, preferably
C.-C, alkyl oromn (eo methyl ethyl n-propyl isopropyl, n-butyl, isobutyl, tert-butyl, n-pentvl or n-hexyl), or R’ and R'° together with the nitrogen atom to which they are attached form a 4- to 7-itnembered saturated heterocycle (preferably pyrrolidinyl or piperidinyl).
R'! and R'? each independently represent a hydrogen atom or a C;-Cg, preferably
C;-Cy, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by a C,-Cg, preferably C;-C,, alkoxycarbonyl substituent group. rR" represents a hydrogen atom or a C;-Cg, preferably C,-C,, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl).
RY represents a hydrogen atom, or a C;-Cg, preferably C,-C,, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl, C;-Cg, preferably C;-Cy, alkoxy or C,-Cg, preferably
C,-C4, alkoxycarbonyl.
RY represents carboxyl, C;-Cg, preferably C;-C,, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C-Cg, preferably C,-C,, alkylcarbonyl (e.g. methylcarbonyl, ‘ ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or 5s n-hexylcarbonyl), C;-Cq, preferably C,-C,, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), C;-Cg alkoxycarbonylC;-Cg alkyl, preferably
C,-C, alkoxycarbonylC,-C, alkyl (e.g. methoxycarbonylmethyl or methoxycarbonylethyl), ora group -NR''R'®, NHSO,CH;, -C(O)NR''R'®, -NHC(O)NR''R'?, -0C(O)NR''R'®, -OCH,C(O)NR''R®, -NHC(0)OR" or -NHC(O)R*". :
It is preferred that Rr! represents C;-C4 alkoxy (especially methoxy), C;-C, alkylcarbonyl (especially methylcarbonyl or ethylcarbonyl), C;-C4 alkoxycarbonylC-C, alkyl (particularly methoxycarbonylmethyl or methoxycarbonylethyl), _C(O)NR!R®, -NHSO,CH;, -NHC(O)NR''R'® or, especially, -NHC(O)R™,
Is
Fach R'® independently represents halogen (e.g. chlorine, fluorine, bromine or iodine), cyano, nitro, carboxyl, hydroxyl, C3-Cg cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), C;-Cg, preferably C;-Cy, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C;-Cq, preferably C;-C,, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), C,-Cg, preferably C;-C,, haloalkyl (e.g. trifluoromethyl),
C,-Cq, preferably C,-C,, haloalkoxy (e.g. trifluoromethoxy), NR*'R%,
C3-Cg cycloalkylamino (e.g. cyclopropylamino, cyclobutylamino, cyclopentylamino or cyclohexylamino), C;-Cq, preferably C;-C,, alkylthio (e.g. methylthio or ethylthio),
C;-Cq, preferably C,-C,, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, 2s n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or . n-hexylcarbonyl), C,-Cg, preferably C;-Cy, alkylcarbonylamino (e.g. methylcarbonylamino or ethylcarbonylamino), sulphonamido,
C,-Cs, preferably C,-Cy, alkylsulphonyl (e.g. methylsulphonyl, ethylsulphonyl, n-propylsulphonyl, isopropylsulphonyl, n-butylsulphonyl, n-pentylsulphonyl or n-hexylsulphonyl), _C(O)NRZR* NR*C(0)-(NH),R*, phenyl, or
C;-Cq, preferably C,-Cy, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxy! or C,-Cg, preferably
C-Cy, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl). 5s Preferably, cach R'e independently represents halogen (particularly chlorine or fluorine), : cyano, Cy-Cy4 alkoxy {especially methoxy), C,-C, alkoxycarbonyl! {especially methoxycarbonyl), C,-C, haloalkyl (especially trifluoromethyl), C;-C, alkylcarbonyl (particularly methylcarbonyl), phenyl or C;-C, alkyl (e.g. methyl or tert-butyl). vw Rand R'® each independently represent a hydrogen atom or a C;-Cy, preferably
C,-Cy, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl or, more preferably,
C,-Cg, preferably C-C,, alkoxycarbonyl, especially methoxycarbonyl, or R'” and R'® together wilh (he nilivgen stom to which they are attached form 2 4- to 7-membered saturated heterocycle (preferably pyrrolidinyl or piperidinyl).
RY represents a hydrogen atom or a C-Cg, preferably C,-Cy, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl or, more preferably, C,-Cs, preferably C,-C,, alkoxycarbonyl, especially methoxycarbonyl. rR represents a group C,-Cg, preferably C,-Cs, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-penty! or n-hexy!), C,-Cg, preferably
C,-Cy, alkenyl, C5-Cq4 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), 2s adamantyl, Cs-Cg cycloalkenyl, phenyl! or a saturated or unsaturated 5- to 10-membered heterocyclic ring system comprising at least one heteroatom (e.g. one, two, three or four ) heteroatoms) selected from nitrogen, oxygen and sulphur, each of which may be optionally substituted by one or more (e.g. one, two, three or four) substituents independently selected from nitro, hydroxyl, oxo, halogen (e.g. fluorine, chlorine, bromine or iodine), carboxyl,
Cy-Cg, preferably C,-Ca, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
tert-butyl, n-pentyl or n-hexyl), C;-Cg, preferably C,-C,, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C;-Cg, preferably C;-Cy,, alkylthio (e.g. methylthio or ethylthio),
C,-Cq, preferably C,-C,, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, . n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), C,-C, preferably C,-C,, alkoxycarbonyl (e.g. methoxycarbonyl or : ethoxycarbonyl), phenyl and _NHC(0)-R?".
The saturated or unsaturated 5- to 10-membered heterocyclic ring system may be monocyclic or polycyclic (e.g. bicyclic) and may comprise up to four heteroatoms independently selected from nitrogen, oxygen and sulphur. Examples of ring systems that may be used include pyrrolidinyl, piperidinyl, pyrazolyl, thiazolidinyl, thienyl, isoxazolyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, quinolinyl, benzimidazolyl, triazolyl, tetrazolyl and pyridinyl. is R*! and R* each independently represent a hydrogen atom or a C;-Cg, preferably
C,-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl,’ n-pentyl or n-hexyl), or R*! and R?? together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocycle (preferably pyrrolidinyl or piperidinyl).
R* and R?* each independently represent a hydrogen atom or a C;-Cg, preferably
C,-Cy4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by a C{-Cg, preferably C;-C4, alkoxycarbonyl substituent group. : - R> represents a hydrogen atom or a C,-Cg, preferably C,-C,, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl).
R*® represents a hydrogen atom, or a C;-Cg, preferably C;-C,, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl, C,-Cy, preferably C,-Cy, alkoxy or C;-Cg, preferably
C4-Cy, alkoxycarbonyl.
RY represents a C-Cg, preferably C,-C,, alkyl group (e.g. methyl, ethyl, n-propyl, . isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), amine or phenyl group.
Preferred compounds of the invention include:
N-[2-(3-{[1-(3,4-dichlorobenzylpiperidinyl Jaminohydroxypropoxy)phenyl jacetamide,
N-[5-chloro-2-(3- {[1-(3,4-dichlorobenzyl)-4-piperidinylJamino}-2- hydroxypropoxy)phenyl]acetamide,
N-[2-(3- {[1-(3,4-dichlorobenzyl)-4-piperidinyl]amino}-2-hydroxypropoxy)-5- methylphenyl]acetamide,
N-[4-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinylJamino} -2-hydroxypropoxy)[1,1'- hipheny!l-2.ylacetamide,
N-[3-acetyl-2-(3- {[1-(3,4-dichlorobenzyl)-4-piperidinyl Jamino } -2-hydroxypropoxy)- 5-mcthylphenyljacctamide,
N-[2-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinylJamino} -2-hydroxypropoxy)-4- fluorophenyl]acetamide,
N-[2-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinyl]amino } -2-hydroxypropoxy)-5- fluorophenyl]acetamide,
N-[2-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinyl]Jamino} -2-hydroxypropoxy)-5- cyanophenyljacetamide,
N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinyllamine} -2-hydroxypropoxy)phenyl]- acetamide,
N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl]amin0} -hydroxypropoxy)phenyl]- isobutyramide, -
N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinylJamino}-2 -hydroxypropoxy)phenyl]-2-2- dimethyl-propiomanide,
N-[5-chloro-2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl]amino}-2- hydroxypropoxy)phenyljacetamide,
N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl]amino}-2-hydroxypropoxy)-5- methylphenyl]acetamide,
N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl]Jamino}-2-hydroxypropoxy)-4- . methylphenyl]acetamide, :
N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl amino} -2-hydroxypropoxy)-4- fluorophenyl]acetamide,
N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinylJamino}-2-hydroxypropoxy)-5- cyanophenyl]acetamide,
N-(2-{[(2S)-3-({-[(4-Chlorophenyl)methyl]-4-piperidinyl } amino)-2- hydroxypropyl]oxy}phenyl)acetamide bi(trifluoroacetate), 'N-(2-{(2R)-3-[1-(4-Chloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-2-methyl- propoxy}-phenyl)-acetamide,
N-(2-{[3-({1-[(4-Chlorophenyl)methyl]-4-piperidinyl } amino)-2-hydroxy-2- methylpropylloxy}phenyl)acetamide,
N-(2-{(2S)-3-[1-(4-Chloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-2-methyl- propoxy }-phenyl)-acetamide,
N-{2-[((2S)-3-{[1-(4-Fluorobenzyl)-4-piperidinylJamino}-2- hydroxypropyl)oxy]phenyl} acetamide,
N-{2-[((2S)-3-{[1-(4-Chlorobenzyl)-4-piperidinyl Jamino}-2-hydroxypropyl)oxy]-4- fluorophenyl}acetamide,
N-{4-fluoro-2-[((2S)-3-{[1-(4-fluorobenzyl)-4-piperidinylJamino} -2- hydroxypropyl)oxy]phenyl} acetamide,
N-{2-[((2S)-3-{[(39)-1 ~(4-Chlorobenzyl)pyrrolidiny!] amino} -2-hydroxypropyl)oxy]-. 4-fluorophenyl} acetamide,
N-{2-[((25)-3-{[(3R)-1-(4-Chlorobenzyl)pyrrolidinyl]amino} -2-hydroxypropyl)oxy]- : 4-fluorophenyl} acetamide,
N-[2-(3-{[1-(4-Fluorobenzyl)-4-piperidinyl]amino}-2-hydroxy-2- methylpropoxy)phenyl]acetamide,
N-[2-(3-{[1-(4-Chlorobenzy!)-4-piperidinyl]Jamino}-2-hydroxy-2-methylpropoxy)-4- fluorophenyljacetamide, .
N-{4-Fluoro-2-(3-{[1-(4-fluorobenzyl)-4-piperidinyl]amino} -2-hydroxy-2- methylpropoxy)phenyljacetamide,
N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinyl]Jamino } -2-hydroxypropoxy)-4- methylphenyl]acetamide, :
N-{2-(3- {[1-{4-Fluorobenzyl)-4-piperidinyljamino} -2-hydroxypropoxy)-4- methylphenyijacetamide,
N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinylJamino}-2- hydroxypropoxy)phenyllbenzamide,
N-[2-(3-{[1-(4-Fluorobenzyl)-4-piperidinyl]amino}-2- hydroxypropoxy)phenyllbenzamide,
N-[2-(3-{[(3S)-1-(4-Chlorobenzyl)pyrrolidinyl]amino} -2- hydroxypropoxy)phenyllbenzamide,
N-[2-(3-{[(3R)-1-(4-Chlorobenzyl)pyrrolidinylJamino} -2- hydroxypropoay phenyl jbenzamide, is N-[2-(3-{[!-(4-Bromobenzy!)-4-piperidinyl]aminc}-2- hydroxypropoxy)phenyljbenzamide,
N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinyl]amino}-2-hydroxy-2- methylpropoxy)phenyl]benzamide,
N-[2-(3-{[1-(4-Fluorobenzyl)-4-piperidinyl]amino}-2-hydroxy-2- methylpropoxy)phenyl]benzamide,
N-[2-(3-{[(3R)-1-(4-Chlorobenzyl)pyrrolidinyl]lamino } -2-hydroxy-2- methylpropoxy)phenyl]benzamide,
N-{2-(3-{[1-(4-Bromobenzyl)-4-piperidinyl]amino } -2-hydroxy-2- methylpropoxy)phenyl]benzamide,
N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinyl]amino } -2-hydroxypropoxy)-4- methoxyphenyl]acetamide, i
N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinyl]amino }-2-hydroxypropoxy)-6- fluorophenyl]acetamide,
N-[2-Fluoro-6-(3-{[1-(4-fluorobenzy!)-4-piperidinylJamino}-2- hydroxypropoxy)phenyljacetamide,
2-(3-{[1-(4-Chlorobenzyl)-4-piperidinylJamino}-2-hydroxy-2-methylpropoxy)-N- methylbenzamide,
N-(2-{3-[1-(3,4-Dichloro-benzyl)-piperidin-4-ylamino}-2-hydroxy-propoxy} -phenyl)- . benzamide,
N-(2-{3-[1-(3-Chloro-4-fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}- phenyl)-benzamide,
N-(2-{3-[1-(3,4-Difluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy} -phenyl)- benzamide,
N-(2-{3-[1-(3,4-Dichloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}-6- methyl-phenyl)-acetamide,
N-(2-{3-[1-(4-Fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}-6-methyl- phenyl)-acetamide,
N-(2- {3-[1-(4-Bromo-benzyl)-piperidin-4-ylamino]-2-hydroxy-2-methyl-propoxy} - phenyl)-acetamide,
N-(2-{3-[1-(3,4-Dichloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-2-methyl- propoxy }-phenyl)-acetamide,
N-(2- {3-[1-(3-Chloro-4-fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-2-methyl- propoxy}-phenyl)-acetamide,
N-(2-{3-[1-(3,4-Difluoro-benzyl)-piperidin-4-ylamino}-2-hydroxy-2-methy]l- propoxy}-phenyl)-acetamide, 2-{3-[1-(4-Bromo-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}-N-methyl- benzamide, 2-{3-[1-(3,4-Dichloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy } -N-methyl- benzamide, 2-{3-[1 -(4-Chloro-benzyl)-piperidin-4-ylamino] -2-hydroxy-propoxy}-N-methyl- benzamide, 2-{3-[1-(4-Fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy }-N-methyl- benzamide, 3,5-Dimethyl-1H-pyrrole-2-carboxylic acid (2-{3-[1-(4-bromo-benzyl)-piperidin-4- ylamino]-2-hydroxy-propoxy}-phenyl)-amide,
3,5-Dimethyl-1H-pyrrole-2-carboxylic acid (2-{3-[1-(3-chloro-benzyl)-piperidin-4- ylamino]-2-hydroxy-propoxy} -phenyl)-amide, 3,5-Dimethyl-1H-pyrrole-2-carboxylic acid (2-{3-{1-(3-fluoro-benzyl)-piperidin-4- ylamino]-2-hydroxy-propoxy}-phenyl)-amide, ‘
N-(2-{3-[1-(4-Bromo-benzyi)-piperidin-4-ylamino}-2-hydroxy-propoxy } -plienyl)- acetamide,
N-(2-{3-[1-(3-Chloro-4-fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy} - phenyl)-acetamide,
N-(2-{3-[1-(3,4-Ditluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy} -phenyt)- acetamide, and
N-(2-{3-[1 ~(4-Fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy} -phenyl)- acetamide.
The present invention furicr provides a process for the preparation of a compound of i5 formula (I) as defincd above which comprises (a) reacting a compound of general formula ; Na
Fo Le A 7 z'7 NH, (RY) " (II) wherein m, n, z', z’, R' and R? are as defined in formula (I), with a compound of general formula 0._R 4 ~~ 2
CER OR
4 6 -
RR (IIT) . 2 54 55 pb 7 8 . wherein Q, R”, R', R™, R", R" and R" are as defined in formula (I); or (b) reacting a compound of general formula
R) Na R* ] R® i ’ m
JEN
R% SE 0 ®) R aw) wherein m, n, z, 72 rR! rR’, rR? R>, RS, rR’ and Rr? are as defined in formula (I), with a compound of general formula 1 2
L' -Q-R Vv) wherein L' represents a hydrogen atom or a leaving group (e.g. Li when Q is CH,) and Q and R? are as defined in formula @); or (c) reacting a compound of general formula ~N2 1 N Zz
ES
1
R3 z Oo (Rn (VD) wherein m, n, z! 72 Rr! and R> are as defined in formula (I), with a compound of general ts formula
HOR’ 4
HN Np2
ROR vp wherein Q, rR’, RY, Rr’, RS, R’ and R® are as defined in formula (1); and optionally after (a), (b) or (c) converting the compound of formula (I) to a further compound of formula (I) and/or forming a pharmaceutically acceptable salt or solvate of the compound of formula (I).
The process of the invention may conveniently be carried out in a solvent, e.g. an organic solvent such as an alcohol (e.g. methanol or ethanol), a hydrocarbon (e.g. toluene) or acetonitrile at a temperature of, for example, 15°C or above such as a temperature in the range from 20 to 120°C. .
Compounds of formulae (II), (IIL), IV), (V), (VI) and (VII) are either commercially available, are well known in the literature or may be prepared easily using known techniques.
Compounds of formula (I) can be converted into further compounds of formula (I) using standard procedures. For example, a compound of formula (I) in which RY represents -NHC(O)CHj can be converted to a further compound of formula (I) in which RP represents -N1, by a hydrolysis reaction in the presence of hydrochloric acid. 1s It will be appreciated by those skilled in the art that in the process of the present invention certain functional groups such as hydroxy! or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups.
The protection and deprotection of functional groups is described in Protective Groups in
Organic Chemistry’, edited by J. W.F. McOmie, Plenum Press (1973) and 'Protective
Groups in Organic Synthesis’, 2nd edition, T.W. Greene and P.G.M. Wuts, Wiley-
Interscience (1991).
The compounds of formula (I) above may be converted to a pharmaceutically acceptable ~ salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or p-toluenesulphonate.
Compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses the use of all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. The use of . tautomers and mixtures thereof also form an aspect of the present invention. Preferred . . s optical isomers are the (S)-enantiomers. Co
The compounds of formula (IT) have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially MIP-1a chemokine receptor) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative and hyperproliferative to diseases and immunologically-mediated diseases including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS).
Examples of these conditions are: (1) (the respiratory tract) airways diseases including chronic obstructive pulmonary disease (COPD) such as irreversible COPD; asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer’s lung and related diseases, fibroid lung and idiopathic interstitial pneumonia; (2) (bone and joints) rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter’s disease), Behcet's disease, - Sjogren’s syndrome and systemic sclerosis; (3) (skin) psoriasis, atopical dermatitis, contact dermatitis and other eczmatous dermitides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus,
Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis; (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinopilic gastro-enteritis, ‘ mastocytosis, Crohn’s diseasc, ulcerative colitis, food-related allergies which have effects remote from the gut, €.g., migraine, rhinitis and eczema; (5) (other tissues and systemic disease) multiple sclerosis, atherosclerosis, Acquired
Immunodeficiency Syndrome (A1DS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto’s thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, sezary syndrome and idiopathic thrombocytopenia pupura; kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease; (7) cancers, especially non-small cell lung cancer (NSCLC) and squamous sarcoma; (8) diseases in which angiogenesis is associated with raised chemokine levels (e.g.
NSCLC); and (9) cystic fibrosis, stroke, re-perfusion injury in the heart, brain, peripheral limbs and sepsis.
Thus, the present invention provides a compound of formula (I), or a pharmaceutically- - acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.
Inthe context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.
The invention also provides a method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined. )
The invention still further provides a method of treating an airways disease in a patient 1s suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The daily dosage of the compound of formula (I) may be in the range from 0.001 mg/kg to 30 mg/kg.
The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a . pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w,
still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.
The present invention also provides a pharmaceutical composition comprising a compound : sof formula (I), or a pharmaccutically acceptable salt or solvate thereof, as hereinbefore defined, in associaiion wilh a pharinaceutically acceptable adjuvant, diluent or carrier.
The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.
The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways oi to the skin) inthe form of solutions, suspensions. heptafinoraalkane nernsnle
QLLVW AYO UL WU aL ondid) dad HAO JULIE OF SUILILILLL, BE CAEEISEE ES te Liepiidliiningg LALIT IL AIA ts and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.
The invention will now be further explained by reference to the following illustrative examples, in which '"H NMR spectra were recorded on Varian Unity Inova 400. The central solvent peak of chloroform—d (3; 7.27 ppm) were used as internal standard. Low resolution mass spectra and accurate mass determination were recorded on a Hewlett-
Packard 1100 LC-MS system equipped with APCI /ESI ionisation chambers. 2s All solvents and commercial reagents were laboratory grade and used as received.
The nomenclature used for the compounds was generated with ACD/IUPAC Name Pro. )
Examples 1-16
Starting material: 1-(3 ,4-Dichlorobenzyl)-4-piperidinylamine i) tert-Butyl 4-piperidinylcarbamate
Di-tert-butyl-dicarbonate (11.6g, 53.16mmol) was added to a solution of 1-benzyl-4- piperidinamine (13.10g, 68.84mmol) in dichloromethane (100ml) and triethylamine (2ml) and the solution was stirred at room temperature for 2 hrs. Water was added to the solution s and the organic layer was separated, dried over natrium sulphate, filtered and concentrated.
The resulting residue was taken up into ethanol. Palladium hydroxide 20% (500mg) was added to the solution and the mixture was hydrogenated (parr apparatus) over 50psig hydrogen for 48 hrs. The mixture was filtered over a pad of celite. The solid was washed with two portions of hot ethanol and concentrated in vacuo to give 8.85g product.
APCI-MS: m/z 201[MH+] "HNMR (400MHz, CD;0D) 6 2.97-3.39(1H, m), 3 (2H, m), 2.55-2.62 (2H, m), 1.8-1,84 (2H,dd), 1.42 (94, s), 1.27-1.37 (2H,m) is ii) 1-(3,4-Dichlorobenzyl)-4-piperidinylamine 1,2-dichloro-4-(chloromethyl)benzene (390mg, 1.99mmol) ) was added to a solution of tert-butyl 4-piperidinylcarbamate (400mg, 2.0mmol) in DMF (25ml) and triethylamine (2ml). The solution was stirred at room temperature for 3hrs and then concentrated in vacuo. To the solution of the solid in dichloromethane was added (30ml) trifluoroacetic acid (6ml) was added and stirred at room temperature for 2hrs. The solution was diluted with dichloromethane and washed with two portions of water. The combined water washings were treated with 2M NaOH to pH 10 and extracted with ether. The ether was dried (Na, S0O,), filtered and evaporated to leave a yellow residue (300mg, 1.16mmol). 2s APCI-MS: m/z 259[MH+] . "HNMR (400MHz, CD5;0D) 3 7.41(1H, d), 7.36 (1H, br d), 7.13 (1H, dd), 3.42 (2H, s), 2.97-3.01 (1H, m), 3 (2H, m), 2.55-2.62 (2H, m), 1.41-1.55 (2H,dd), 1.31-1.54 (2H,m)
Example 1
N-[2-(3-{[1-(3,4-dichlorobenzylpiperidinyl]aminohydroxypropoxy)phenyl]acetamide
The mixture of N-Acetyl-2-(2,3-epoxypropoxy)aniline (120mg, 0,58mmol) and the above starting material (150mg, 0,58mmol) in ethanol (10ml 99.5%) was refluxed for 3hrs. The solvent distilled off under reduced pressure, the resulting residue was purified by silica gel column chromatography (eluant: dichloromethane/methanol 15:1) to give 108mg of the title compound as a gum. Addition of 1.0M ethereal HCI solution gave a white solid product.
APCI-MS:m/z 466[MH'] io 'HNMR (400MHz, CD,0D) &§ 8.0 (1H, dd,), 7.5 (1H, d), 7.45 (1H d), 7.23 (1H, dd), 6.89- 7.08 (4H, m), 4.15 (1H, m), 3.9-4.1 (2H, m), 3.40 (2H, S), 2.97-3.11 (1H, m), 3 (2H, m), 2.55-2.68 (2H, m), 1.39-1.55 (2H,dd), 1.31-1.44 (2H,m), 2.17 (3H, s).
The following compounds wore synthesised by methods analogous fo the method 1s described in Example 1.
Example 2
N-[5-chloro-2-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinyl]amino}-2- hydroxypropoxy)phenyljacetamide
APCI-MS: m/z 500[MH"]
Example 3
N-[2-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinyl]amino}-2-hydroxypropoxy)-5- 2s methylphenyl]acetamide
APCI-MS: m/z 480[MH"]
Example 4
N-[4-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinyl]amino}-2-hydroxypropoxy)[1,1'- biphenyl}-3-yl]acetamide
APCI-MS: m/z 542[MH"]
Example 5 ~~ N-[3-acetyl-2-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinyl]amino}-2-hydroxypropoxy)-5- methylphenyljacetamide ‘10 APCI-MS: m/z 522[MH"]
Example 6
N-[2-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinyl]amine}-2-hydroxypropoxy)-4- fluorophenyljacetamide
APCI-MS: nv/z 484[MH"]
Example 7
N-[2-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinyl]amino}-2-hydroxypropoxy)-5- fluorophenyl]acetamide
APCI-MS: m/z 484[MH"]
Example 8
N-[2-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinylJamino}-2-hydroxypropoxy)-5- ‘ cyanophenyl]acetamide
APCI-MS: m/z 491[MH"]
Example 9 :
N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl]amino}-2-hydroxypropoxy)phenyl}- acetamide
APCI-MS: m/z 432[MH"]
Example 16
N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl]amin0}-hydroxypropoxy)phenyl]- isobutyramide
APCI-MS: m/z 460[MH")
Example 11
N-[2-(3-{]1-(4-chlorobenzyl)-4-piperidinyljamino}-2-hydroxypropoxy)phenyl}-2-2-
APCI-MS: m/z 474[MH"]
Example 12
N-[5-chloro-2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl]Jamino}-2- hydroxypropoxy)phenyljacetamide
APCI-MS: m/z 466[MH")
Example 13
N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl]amino}-2-hydroxypropoxy)-5- methylphenyljacetamide '
APCI-MS: m/z 446[MH")
Example 14
N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl]Jamino}-2-hydroxypropoxy)-4- methylphenyljacetamide
APCI-MS: m/z 446[MH"]
Example 15
N-{2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl]amino}-2-hydroxypropoxy)-4- fluorophenyl}acetamide
APCI-MS: m/z 450[MH"]
Example 16
N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl}]amino}-2-hydroxypropoxy)-5- cyanophenyljacetamide
APCI-MS: m/z 457[MH"]
Starting Materials for Examples 17 to 63.
Epoxide: A
N-{2-[(28)Oxiranylmethoxy]phenyl}acetamide ) (2S)-2-[(2-nitrophenoxy)methyl]oxirane (1.17 g, 6 mmol) was dissolved in ethyl acetate (50 ml). Platinum on charcoal (0.50 g) was added, and the mixture was stirred in the atmosphere of hydrogen for 3 h at room temperature and atmospheric pressure. The catalyst was filtered and washed on the filter with ethyl acetate (10 ml). Acetic anhydride : (1.23g, 1.13. ml, 12 mmol) and ethyldi(i-propyl)amine (1.55 g, 2.05 ml, 12 mmol) were added to the solution. The reaction mixture was stirred at room temperature for 3 h, then washed with 1M NaOH (2 x 50 ml) and brine (2 x 50 ml), and dried with Na,SO,.
Evaporation of the solvent and flash chromatography on silica gel with n-heptane/ethyl acetate (from 25 to 75 %) afforded the title compound (0.74 g, 3.57 mmol, 60 %) as colourless crystals. "H-NMR (400MHz, CDCL,): & 8.36 (m, 1H), 7.89 (br. S, 1H), 6.8 — 7.0 (m, 3H), 4.35 (dd, : so WL J=2350=113)395(dd, 1H, J=597=17113,330(m, 1H),295(, 1H J=48), 2.78(dd, 111, J =2.7, J =4.8),2.22 (s, 311).
APCI-MS: m/z 208 [MH']
Epoxide: B 1) [(2R)-2-Methyloxiranyl]methyl-4-methylbenzenesulfonate (S)-2-methyl-glycidol (0,10g, 1.13mmol), dimethylaminopyridine (0.5mg, 3.8umol) in triethylamine (2ml) was cooled on an ice bath and tosyl chloride (0.217g, 1.14mmol) was added in portions during 10 min. The flask was sealed and kept at —10°C over night. The reaction mixture was evaporated and the residue was stirred with dry diethylether (2 Sm), 1s The solid was filtered off and washed with diethylether ( 3 x 1m). The filtrate was dried and concentrated in vacuo. The crude product was purified on silica (Ileptane/EtOAc 1:2) to give 145mg (53%) of the subtitle compound. 'H-NMR (400MHz, CDCL,): § 7.80 (2H, d, J8.4Hz), 7.36 (2H, d, J8.1Hz), 4.04 (1H, d,
J10.7Hz), 3.95 (1H, 4, J10.7Hz), 2.70 (1H, d, J4.7Hz), 2.64 (1H, d, J4.6Hz), 2.46 (3H, s), 1.36 3H, s). ii) N-2-{[(2R)-2-Methyloxiranyl]methoxy}phenyl)acetamide
To 2-acetamidophenol (90.5mg, 0.598mmol) and cesium carbonate( 234mg, 0.718mmol) 35 was added [(2R)-2-methyloxiranyl]methyl 4-methylbenzene-sulfonate (145mg, 0.598mmol) dissolved in DMF (1ml). The mixture was stirred at room temperature for four hours and then partitioned between ethyl-acetate and water. After extraction the combined organic phases were dried and concentrated in vacuo. The residue was purified on silica (Heptane/EtOAc 3:1 — 2:1) to give 63mg (48%) of the title compound.
'H-NMR (400MHz, CDC1,): 3 8.38-8.31 (1H, m), 8.02 (1H, bs), 7.04-6.97 (2H, m), 6.93- 6.86 (1H, m), 4.11 (1H, d, J10.9Hz), 4.01 (1H, d, J10.9Hz), 2.95 (1H, d, J4.7Hz), 2.78 (1H, d, J4.7Hz), 2.21 (3H, 5), 1.48 (3H, 5). s Epoxide: C i) [(2S)-2-Methyloxiranyljmethyl-3-nitrobenzenesulfonate
To an oven-dried 1000 ml three-necked flask was added powdered activated molecular sieves (8.0 g, 4A) and CH, Cl, (440 ml, dried over molecular sieves). D-(-)-Diisopropyl tartrate (3.0 ml, 14.2 mmol) and 2-methyl-2-propan-1-ol (20 ml, 240 mmol) was added and the mixture was cooled to ~20°C. Titanium tetraisopropoxide (3.5 ml, 11.9 mmol) was added with a few ml of CH,Cl, and the mixture was stirred at —20°C for 30 minutes.
Cumene hydroperoxide (75 ml, approx. 430 mmol) was added dropwise over 1.5 hours maintaining the temperature at 20°C. The mixture was stirred at this temperature over night. Trimethylphosphite (40 ml, 340 mmol)was added dropwise over 5 hours maintaining ts the temperature at —20°C. Triethylamine (50 ml, 360 mmol) and DMAP (3.48 g, 28.5 mmol) was added followed by a solution of 3-nitrobenzenesulphony] chloride (47 g, 212 mmol) in CH,Cl, (400 ml). The temperature was raised to —10°Cand the mixture was stirred at this temperature over night. After removing the external cooling, the reaction mixture was filtered through celite®. The organic phase was washed with 10% tartaric acid (500 ml), saturated NaHCO, (300 ml) and brine (300 ml). The organic phase was dried (MgSO0,) and evaporated to give ca 150 g of a yellow oil. The crude material was chromatographed (1 kg silica, Heptane/EtOAc 100:0 to 50:50 gradually increased polarity) to give 48.8 g (84%) of the sub-title compound as a yellow oil. The compound was pure enough to use further without any additional purification. i "H-NMR (400 MHz, CDCl,): O 8.79-8.75 (1H, m); 8.52 (1H, ddd, J 1.1 2.3 8.3 Hz); 8.25 (1H, ddd,/J 1.1 1.8 7.8 Hz); 7.81 (1H, t, J 8.5 Hz); 4.28 (1H, d, J 11.3 Hz); 4.05 (1H, d, J 11.3 Hz); 2.73 (1H, d, J 4.4 Hz); 2.67 (1H, d, J 4.4 Hz); 1.56 (3H, 5) ii) V-(2-{[(25)-2-Methyloxiranyllmethoxy}phenyl)acetamide
In a flask was added the compound obtained in a) (24.57 g, 90 mmol), 2-acetamido-phenol (13.59 g, 90 mmol), Cs,CO, (35.1 g, 108 mmol, powdered anhydrous) and DMF (90 ml).
The flask was sealed and the mixture was stirred with a magnetic stirrer at room temperature for 2 hours. A heavy precipitate was formed, and the starting materials were s converted in 2 hours The mixture was partitioned between EtQOAc/water (400 + 400 ml).
The organic phase was collected and the aqueous phase was washed with EtOAc (2 x 200 ml). The combined organic phases were washed with water (200 ml), 1M NaOH (2 x 200 ml) and brine (150 mi). The organic solution was dried over Na,SO,, and conceniraied in vacuo after filtration. The crude material was purified on silica (Heptane/EtOAc 5:1 to 1:1, gradually increasing the polarity), eluting 18.5 g (92%) of the sub-title compound. The optical purity was 97.4 %, according to chiral HPLC (Chiralpak ™, iso-hexane/iso- propanol 95:5). "H-NMR (400 MHz. CDCL): 1M 839-832 (1H, m): 8.00 (1H, bs): 7.05-6.97 (2H. m); 6.95- is 6.88 (1H, m); 4.12 (1H, d, AB, J 11.0 Hz); 4.02 (1H, d, AB, J 11.0 Hz); 2.96 (1H, d, J 4.6
Hz), 2.79 (1H, d, J4.8 Hz); 2.22 (3H, 5); 1.49 (3H, 5)
Epoxide: D
N-{4-Fluoro-2-[(28)oxiranylmethoxy]phenyl}acetamide was prepared from (2S5)-2-[(5-fluoro-2-nitrophenoxy)methyl]oxirane according to the method described for Epoxide: A.
APCI-MS: m/z 226 [MH+] 'H-NMR (400MHz, CDCl): 6 8.30 (dd, 1H, J = 5.2, J = 9.0), 7.71 (br. S, 1H), 8.6 — 8.8 2s (m,2H),4.36 (dd, 1H,J=2.3,J=113),390(dd, 1H,J=6.3, J=11.3),3.40 (m, 1H), 297(t, 1H, J =4.4),2.78 (dd, IH, J=2.7, J = 4.8), 2.21 (s, 3H). .
Epoxide: E
N-{2-[(2-Methyl-2-oxiranyl)methoxy]phenyl}benzamide
A mixture of N-(2-hydroxyphenyl)benzamide (159 mg, 0.75 mmol), 2-(chloromethyl)-2- methyloxirane (1.60 g, 15 mmol), and benzyltriethylammonium chloride (27 mg, 0.12 mmol) was stirred at 70 — 75 °C for 6 h. After cooling to room temperature, water (2 ml) was added and the mixture was vigorously shaken. It was extracted with dichloromethane (2x5 ml), and the combined organic extracts were washed with aq. NaOH (2M, 5 ml) and water (10 ml). Drying with Na,SO,, evaporation of the solvent and flash chromatography on silica gel with n-heptane/ethy] acetate (ethyl acetate from 25 to 50 %) afforded title compound as yellowish solid (131 mg, 0.46 mmol, 62 %).
APCI-MS: m/z 284 [MH+] "H-NMR (400MHz, CDCL): 8 8.68 (br. S, 1H), 8.54 (m, 1H), 7.94 (m, 2H), 7.4 — 7.6 (m, : 3H), 7.07 (m, 2H), 6.92 (m, 1H), 4.19 (d, 1H, J = 10.7), 4.06 (4, 1H, J 10.7), 2.92 (4, 1H, J =4.6),2.78 (d, 1H, J = 4.6).
Epoxide: F
N-Methyl-2-[(2-methyl-2-oxiranyl)methoxy]benzamide was prepared from 2-hydroxy-N-methylbenzamide (prepared according to Cohen et al, J.
Am. Chem. Soc.,1998, 20, 6277 - 6286.) according to the method described for N-{2-[(2- methyl-2-oxiranyl)methoxy}phenyl} benzamide.
APCI-MS: m/z 284 [MH+] 'H-NMR (400MHz, CDCL,): & 8.68 (br. S, 1H), 8.54 (m, 1H), 7.94 (m, 2H), 7.47.6 (m, 3H), 7.07 (m, 2H), 6.92 (m, 1H), 4.19 (d, 1H, J = 10.7), 4.06 (d, 1H, J 10.7),2.92 (d, 1H, J =4.6),2.78 (d, 1H, J = 4.6), 1.51 (s, 3H).
Epoxide: G
N-[4-Methyl-2-(2-oxiranylmethoxy)phenyl]acetamide
A mixture of N-(2-hydroxy-4-methylphenyl)acetamide (10 g, 60 mmol), 2- (bromomethyljoxirane (9.86 g, 72 mmol, 6.0 ml) and potassium carbonate (16.8 g, 120 mmol) in DMF (100 ml) was heated at 55 °C for 2 h. Then the reaction mixture was diluted with ethyl acetate and washed with aq. HCI (1.5 %), aq. sat. NaHCO, and brine.
Evaporation of the solvent and flash chromatography on silica gel with n-heptane/ethyl acetate (ethyl acetate from 35 to 70 %) afforded the title compound (5.65 g, 25 mmol, 43 %).
APCLI-MS: m/z 222 [MH+] "H-NMR (400MHz, CDCl): 6 8.20 (d, 1H, J = 8.2), 7.78 (br. 5, 1H), 6.79 (d, 1H, J = 8.2), 6.70 (s, 1H), 4.32 (dd, 1H, J = 2.5, J = 11.4),3.93 (dd, LH, J = 5.9, J = 11.4), 3.38 (m, 1H), 2.94 (t, 1H, J = 4.8),2.77(dd, 1H, J = 2.7, J = 4.8), 2.29 (s, 3H), 2.19 (s, 3H).
Epoxide: H
N-[4-Methoxy-2-(2-oxiranylmethoxy)phenyl]acetamide
Was prepared from N-(2-hydroxy-4-methoxyphenyl)acetamide according to the method described for N14 methyl-2-(2-oviranyImethoxy)phenvllacetamide using cesium carbonate is instead of potassium carbonate.
APCI-MS: m/z 238 [MH+] "H-NMR (400MHz, CDCl): § 8.20 (d, 1H, J = 8.8), 7.62 (br. s, 1H), 6.4 — 6.6 (m, 2H), 6.70 (s, 1H), 4.32 (dd, 1H,J = 2.5, J=11.3),391 (dd, 1H,J= 6.1, J = 11.3),3.77 (s, 3H), 3.37 (m, 1H), 2.94 (t, 1H,J = 4.8), 2.76 (dd, I1H,J = 2.7, J = 4.8), 2.18 (s, 3H).
Epoxide: I i) 2-Amine-3-fluorophenol
To a stirred solution of 2,6-difluoronitrobenzene (1100mg, 6.9mmol) in dry methanol (20ml) was added a solution of sodium (180mg, 7.8mmol) in dry methanol ( 8 ml). The solution was stirred overnight. After concentration, water was added and the solution was ‘extracted with ether, dried over MgSO,, filtered and concentrated to a yellow residue (870mg.5.08 mmol). To the solution of the yellow residue in dichloromethane (10 ml) boron tribromide (1M in dichloromethane, 10 ml) was added and stirred at room temperature overnight. Water was then added and the solution stirred for further 60 min.
The organic phase was separated and the water phase was extracted with ether. The combined organic phase were dried over MgSO, filtered and concentrated in vacuo to give a brownish residue. The residue was taken up into ether and washed with 2M sodium hydroxide and water. The water and sodium hydroxide washings were combined and s neutralised with 6M HCl and extracted with ether, dried over MgSO, and evaporated to give a yellow residue which was purified by flash chromatography on silica gel with
EtOAc:Heptane: 1:3 as eluant to give the product ( 720mg, 4.6mmol) which was directly suspended with palladium-charcoal (140mg) in water-ethanol (30ml). Sodium borohydride (530mg) was added over a period of 5 min and the suspension was stirred at room to temperature (1h). The catalyst was removed by filtration through a Celite pad. The filtrate was acidified with 6M hydrochloric acid to destroy any residual borohydride, neutralised with 2 M sodium hydroxide, and then extracted with ether. The ethereal extracts were dried over MgSO, and evaporated.
APCI-MS: m/z 128.2 [MH*] ii) N-[2-Fluoro-6-(2-oxiranylmethoxy)phenyl]acetamide
To a stirred solution of 2-amino-3-fluorophenol (300 mg, 2.36 mmol) in water-methanol (10 ml) acetic acid anhydride was added until all 2-amino-3-fluorophenol was consumed.
The solution was concentrated to a residue of N-(2-fluoro-6-hydroxyphenyl) acetamide.
To a mixture of N-(2-fluoro-6-hydroxyphenyl)acetamide (399mg, 2.36mmol) and potassium carbonate (652mg, 4.72mmol) in DMF (5 ml) epibromohydrin (388 mg, 2.8mmol) was added and the mixture was stirred at 70°C for 3hr. Water and ethyl acetate were added, the organic phase separated, dried and concentrated. The resulting residue was purified by RP- HPLC (10- 40 % CH3CN) to give the desired product as a solid (242 } mg,1.08mmol).
APCI-MS: m/z 226 [MH+]
‘H-NMR (400MHz, CDCl): 0 7.15 (m, 1H), 6.87 (br. s, 1H), 6.6 - 6.8 (m, 2H), 4.30 (dd, 1H,J=23,J=11.3),393 (dd, 1H,J =5.7,J=11.3),3.34 (m, 1H), 2.91 (t, IH, J = 4.4), 2.75 (dd, 1H, J = 2.8, J = 4.8), 2.20 (br. 5, 3H). s Epoyxide: J
N-(2-Oxiranylmethoxy-phenyl)-benzamide
To a stirred solution of N-(2-Hydroxy-phenyl)-benzamide (0.81g, 3.80 mmol), and cesium carbonate (1.61g, 4.94 mmoi) in acetonitriie was added epibromohydrin (0.63 ml, 7.60 mmol). After 4 hours the reaction mixture was partitioned between to dichloromethane and water. After evaporation of the organic solvent the residue was crystallised from petroleum ether and diethy! ether yielding (0.741g, 73%).
APCI-MS: m/z 227[MH’ "H-NMR (400 MHz, CCL): 8 R 65 (hs, 1H), R.55 (hs, 1H). 7.94 (d. 2H), 7.53 (m. 3H), 7.08 (bs, 2H), 6.96 (bs, 1H), 4.42 (d, 1H), 4.02, (m, 1H), 3.41 (bs, 1H), 2.96 (s, 1H), 2.80 (s, 1H).
Epoxide: K
N-Methyl-2-oxiranylmethoxy-benzamide
To a solution of 2-Hydroxy-N-methyl-benzamide (0.5g, 3.31 mmol prepared according to
Cohen, Seth Metal J. Am. Chem. Soc., (1998), 120(25), 6277-6286.) and cesium carbonate (2.16g, 6.62mmol) in acetonitrile was added epibromohydrin (0.274mi, 3.31mmol). The mixture was heated at 50°C for 2 hours and then after cooling to room temperature partitioned between water(50 ml)and dichloromethane (100ml). The 2s dichloromethane was dried and evaporated . Chromatography (EtOAc) gave 0.43g (64%) of the product as a solid. -
APCI-MS: m/z 208[MH"]
'H -NMR (400 MHz, CDCl): 8 8.20 (dd, 1H), 7.85 (bs, 1H), 7.42 (m, 1H), 7.11 (m, 1H), 6.95 (dd, 1H), 4.46 (dd, 1H), 4.11 (dd, 1H), 3.41 (m, 1H), 3.02 (d, 3H), 2.97 (t, 1H), 2.84 (dd, 1H). 5s Epoxide: L
N-(2-Methyl)-6-oxiranylmethoxy-phenyl)-acetamide
A mixture of 3-methyl-2-acetamidophenol (0.165g, 1 mmol), and epichlorohydrin (1.84g, 20mmol) was stirred at 70°C to afford a clear solution. Triethylbenzylammonium chloride (0.15g, 1 mmol) was then added and stirring was continued at 125°C for 15 minutes. After cooling to room temperature 1M NaOH solution was added and the solution was extracted with dichloromethane. The organic extract was washed with water and dried. After evaporation of the dichloromethane the resulting brownish oil was purified through silica chromatography 50-70% EtOAc in heptane yielding the product as a colourless oil (0.12g, 0.54mmol).
APCI-MS: m/z 208[MH"]
Epoxide: M 3,5 Dimethyl-1-H-pyrrole-2-carboxylic acid (2-oxiranylmethoxy-phenyl)-acetamide
The compound was prepared from 3,5 Dimethyl-1-H-pyrrole-2-carboxylic acid-(2-phenyl)- acetamide (300 mg, 1.3 mmol) analogously to that described for Epoxide: L.
APCI-MS: m/z 287 [MH'] "H-NMR (400 MHz, CDCL,): § 8.46 (m,1H), 8.31 (m,1H), 6.99 (m,2H), 6.87 (m,1H), 5.85(m,1H), 4.34(m; 1H), 3.92 (m, 1H), 3.36 (m,1H), 2.91 (m,2H), 2.71 (m,1H), 2.47 (m, . 3H), 2.25 (m,3H). (i) 3,5 Dimethyl-1-H-pyrrole-2-carboxylic acid (2-phenyl)-acetamide 2-Aminofenol ( 545mg, 5 mmol), 3,5 dimethyl-1-H-pyrrole-2-carboxylic acid (ii) (695mg, 5 mmol) and HATU (1900mg, 5 mmol) were stirred in DMF (20 ml).
Diisopropylethylamine was added to pH 8. The mixture was stirred overnight and then concentrated. The residue was purified on C18 ( acetonitrile/water 10/90 to 40/60 with 0.5% trifluoroacetic acid ) to give the title compound ( 550 mg, 48% ). s APCI-MS: m/z 231 [MH] "H-NMR (400MHz, CDCl, ): 8 9.22 (s,1H), 7.63 (s, 1H), 7.11(m, 2H), 7.03 (m, 1H), 6.88 (m,1H), 5.88 (s, 1H), 2.44 (s,1H), 2.24 (5,1H). (ii) 3,5 Dimethyl-1-H-pyrrole-2-carboxylic acid
To a solution of ethyl 3,5-dimethyl-2-pyrrolecarboxylate (Aldrich ) (504mg, 3 mmol ) in
THF/H,0/MeOH (5:1:1, 30ml ) was added NaOH ( 480 mg, 12 mmol ) in H,0 ( 12 ml).
The mixture was stirred at 75° C overnight. The homogeneous mixture was washed with ether. To the aqueous layer was added a saturated aqueous KHSO, solution until the pH wage ahont 3. The solution was then extracted with dichloromethane. The extracts were is dried over MgSO, and evaporated. The residue was purified on silica (ethylacetate /methanol 90/10} te give the title compound ( 375 mg, 90 % ).
H-NMR (400MHz, CDCl, ): & 8.75(s,1H), 5.83(s,1H), 2.25(s,1H), 2.38 (s,1H).
Amine: N 1-(4-Chlorobenzyl)-piperidineamine 1-Chloro-4-(chloromethyl)benzene (1.61 g, 10 mmol) was added to a stirred solution of tert-butyl 4-piperidinylcarbamate (2.02 g. 10.1 mmol) and triethylamine (10 ml) in dry
DMF (100 ml). The solution was stirred at room temperature overnight and then the solvent was removed in vacuo. The residue was taken in dichloromethane (150 ml) and trifluoroacetic acid (30 ml) was added. After stirring at room temperature for 3 h, the . solution was diluted with dichloromethane (150 ml), and extracted with water (2 x 150 ml).
The pH of the combined aqueous extracts was adjusted to 10 by addition of 2 M NaOH.
The solution was extracted with ether (3 x 100 ml). Drying with sodium sulfate and evaporation of the solvent afforded the title compound as yellowish oil (1.91 g, 8.5 mmol, ‘H-NMR (400MHz, CDCl,): § 7.2 7.3 (m, 4H), 3.41 (s, 2H), 2.76 (m, 2H), 2.63 (m, 1H), 1.98 (m, 2H), 1.76 (m, 2H), 1.3 ~ 1.6 (m, 4H).APCL-MS: m/z 225 [MH]
Amine: O (38)-1-(4-Chlorobenzyl)-3-pyrrolidinamine was prepared according the method described for Amine: N from tert-butyl (3S)pyrrolidinylcarbamate.
APCI-MS: m/z 211 [MH+] "H-NMR (400MHz, CDCl): § 7.2 — 7.3 (m, 4H), 5.55 (d, 2H), 3.49 (m, 1H), 2.66 (m, 2H), 2.41 (m, 1H), 2.29 (dd, 1H), 2.18 (m, 1H), 1.68 (br. 5, 2H), 1.48 (m, 1H). )
Amine: P (3R)-1-(4-Chlorobenzyl)-3-pyrrolidinamine
Was prepared according the method described for Amine: N from tert-butyl (3R)pyrrolidinylcarbamate. oo
APCI-MS: m/z 211 [MH+] 'H-NMR (400MHz, CDCl,): § 7.2 - 7.3 (m, 4H), 5.55 (d, 2H), 3.49 (m, 1H), 2.66 (m, 2H), 2.41 (m, 1H), 2.29 (dd, 1H), 2.18 (m, 1H), 1.68 (br. s, 2H), 1.48 (m, 1H).
Amine: Q . 3-(4-Chlorophenoxy)piperidine tert-Butyl 3-hydroxy-1-piperidinecarboxylate (1.85 g, 9.18 mmol, prepared according to
Costa et al., J. Med. Chem. 1992, 35, 4334 — 4343) (1.85 g, 9.18 mmol) and triphenyl phosphine (2.41 g, 9.18 mmol) were dissolved in dry THF (25 ml) under nitrogen. The solution was cooled to 0 °C and a solution of 4-chloropheno] (1.18 g, 9.18 mmol) in dry
THF (10 ml) was added followed by diethyl azodicarboxylate (1.60 g, 9.18 mmol, 1.45 ml). After 15 minutes the reaction mixture was allowed to warm to room temperature and stirred overnight. The solvent was removed in vacuo, the residue stirred with ether/n- heptane (1 : 2, 50 ml) mixture. The solid triphenyl phosphine oxide was filtered off, the s solution washed with aq. NaOH (1M, 3 x 75 ml) Evaporation of the solvent and flash chromatography on silica gel with ethyl acetate/n-heptane (ethyl acetate from 5 to 25 %) afforded the BOC-protected subtitle compound, which was dissolved in dichloromethane (20ml). Trifluoroacetic acid (10 mi) was added, and the reaction mixture was stirred overnight at room temperature. The solution was concentrated in vacuo and the product to was purified by flash chromatography on silica gel (MeOH/CHCI,/NH,, 100: 100 : 1) to afford colourless oil (0.23 g, 12%).
APCI-MS: m/z 212 [MH+] "H-NMR (400MHz. CCL): § 7.19 (m, 2H), 6.84 (m_ 2H), 425 (m_ 1H) 3.17 (m. 1H), 2.7 —2.9(m, 4H). 1.97 (m, 1H), 1.7 - 1.9 (m, 2H), 1.53 (m, 1H).
Amine: R : 1-(4-Bromobenzyl)-4-piperidinylamine
To a solution of 4-bromo benzylbromide (1.0g, 4.1mmol) in dichloromethane (20ml) and diisopropyletylamine (1ml) was added tert-butyl 4-piperidinylcarbamate (1.0g, 5.0mmo]l).
The solution was then stirred at room temperature over night. The solvent was evaporated and 25 ml of 50% TFA in dichloromethane was added to the resulting white solid. The mixture was then stirred at room temperature for 2h and then evaporated to dryness. The resulting solid was dissolved in water and extracted with toluene. After removal of the 2s toluene the water phase was made basic with 1M NaOH giving a pH of 13. The water phase was then extracted with dichloromethane 3 times and the combined extracts were : dried and then evaporated to give the pure product as a slightly yellow oil (0.96g, 3.6mmol)
APCI-MS: m/z 269[M+]
"H-NMR (400 MHz, CDCl): 7.42 (d, 2H), 7.18 (d, 2H), 3.43 (s, 2H), 2.78 (m, 3H), 2.43 (bs, 2H), 2.10 (t, 2H), 1.82 (m, 2H), 1.44 (m, 2H).
The following Amines (S, T, U) were synthesised by methods analogous to the method 5s described for Amine R.
Amine: S 1-(3,4-Difluorobenzyl)-4-piperidinylamine
APCI-MS: m/z 227[MH"]
Amine: T 1-(3-Chloro-4-fluorobenzyl)-4-piperidinylamine is APCI-MS: m/z 243[MH"]
Amine: U 1-(4-Fluorobenzyl)-4-piperidinylamine
APCI-MS: m/z 209[MH"]
Example 17 :
N-(2-{[(25)-3-({-[(4-Chlorophenyl)methyl]-4-piperidinyl}amino)-2- hydroxypropyl]Joxy}phenyl)acetamide bi(trifluoroacetate) . A solution of 1-(4-chlorobenzyl)-piperidine amine (0.80 g, 3.57 mmol) and N-{2- [(25)oxiranylmethoxy]phenyl}acetamide (0.74 g, 3.57 mmol) in ethanol (50 ml, 99.5 %) was refluxed for 4h. The solvent was distilled off under reduced pressure. The residue was purified by preparative HPLC (Kromasil C18 column; eluant: [acetonitrile + 0.1 %
TFA/water + 0.1 % TFA]) to afford colourless solid (1.158 g, 1.75 mmol, 49 %).
APCI-MS: m/z 432 [MH]
Example 18
N-(2-{(2R)-3-[1-(4-Chloro-benzyl)-piperidin-4-ylamino}-2-hydroxy-2-methyl- s propoxy}-phenyl)-acetamide 1-(4-chlorobenzyl)-4-piperidinamine (62mg, 0.276mmol) and N-(2-{[(2R)-2- methyloxiranyijmethoxy jphenyi)acetamide (6 img, 0.276mmoi) in ethanoi (i.5mi) was stirred in a sealed vial at 80°C for 4 hours. The reaction mixture was diluted with water and to purified by reversed phase HPLC to give 130mg (70%) of the title compound as a ditrifluoroacetate after lyophilisation. The optical purity was determined to 86% ee, by chiral HPLC on a Chiralpak AD-column.
APCI-MS: m/z446 1 [M+]
Example 19
N-(2-{[3-({1-[(4-Chlorophenyl)methyl]-4-piperidinyl}amino)-2-hydroxy-2- methylpropyljoxy}phenyl)acetamide
Prepared by analogy to the method described in Example 18 from racemic epoxide.
APCI-MS: m/z 446.1 [M+]
Example 20 2s N-(2-{(25)-3-[1-(4-Chloro-benzyl)-piperidin-4-ylamine}-2-hydroxy-2-methyl- propoxy}-phenyl)-acetamide :
Prepared according to the method described in Example 18 from N-(2-(((25)-2- methyloxiranyl)methoxy)phenyl)acetamide, >98% yield was obtained.
APCI-MS: m/z 446.1 [M+]
General Procedure (Examples 21-43)
To a solution of the amine in EtOH (0.1 M, 0.2 ml) a solution of the epoxide in DMSO (0.1 5s M, 0.2 ml) was added. The reaction mixture was heated at 80 °C for 24 h.
Example 21
N-{2-[((28)-3-{[1-(4-Fluorobenzyl)-4-piperidinyljamino}-2- hydroexypropyDoxy]phenyl}acetamide
APCI-MS: m/z 416 [MH+]
Example 22
N-{2-[((28)-3-{[1-(4-Chlorobenzyl)-4-piperidinyllamino}-2-hydroxypropyl)oxy]-4- fluorophenyl}acetamide
APCI-MS: m/z 450 [MH+]
Example 23
N-{4-fluoro-2-[((2S)-3-{[1-(4-fluorobenzyl)-4-piperidinyl]amino}-2- hydroxypropyl)oxy]phenyl}acetamide -
APCI-MS: m/z 434[MH+]
Example 24
N-{2-[((25)-3~{[(35)-1-(4-Chlorobenzyl)pyrrolidinyl]amino}-2-hydroxypropyl)oxy]-4- fluorophenyl}acetamide APCI-MS: m/z 436 [MH+]
Example 25
N-{2-[((25)-3-{[(3R)-1-(4-Chlorobenzyl)pyrrolidinyl]amino}-2-hydroxypropyl)oxy]-4- fluorophenyl}acetamide
APCI-MS: 1v/z 436 [MII]
Example 26
N-[2-(3-{[1-(4-Fluorobenzyl)-4-piperidinyl]amino}-2-hydroxy-2- io methylpropoxy)phenyl]acetamide
APCI-MS: m/z 430 [MH+]
Example 27 1s N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinyl}amino}-2-hydroxy-2-methylpropoxy)-4- fluorophenyljacctamide
APCI-MS: m/z 464 [MH+]
Example 28
N-[4-Fluoro-2-(3-{[1-(4-fluorobenzyl)-4-piperidinyljamino}-2-hydroxy-2- methylpropoxy)phenyljacetamide
APCI-MS: m/z 448 [MH+] oo
Example 29
N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinyljamino}-2-hydroxypropoxy)-4- methylphenyljacetamide APCI-MS: m/z 446 [MH+]
Example 30
N-[2-(3-{[1-(4-Fluorobenzyl)-4-piperidinyl]amino}-2-hydroxypropoxy)-4- methylphenyl]acetamide 3 .
APCI-MS: m/z 430 [MH+]
Example 31
N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinyl]amino}-2- hydroxypropoxy)phenyl]benzamide APCL-MS: m/z 494 [MH+]
Example 32
N-[2-(3-{[1-(4-Fluorobenzyl)-4-piperidinyl]amineo}-2- . hydroxypropoxy)phenyl]benzamide
APCI-MS: m/z 478 [MH+]
Example 33
N-[2-(3-{[(35)-1-(4-Chlorobenzyl)pyrrolidinyl]amino}-2- hydroxypropoxy)phenyl]benzamide
APCI-MS: m/z 480 [MH+] : Example 34
N-[2-(3-{[(3R)-1-(4-Chlorobenzyl)pyrrolidinyl]amino}-2- hydroxypropoxy)phenyl]benzamide APCI-MS: m/z 480 [MH+]
Example 35
N-[2-(3-{[1-(4-Bromobenzyl)-4-piperidinyl]amino}-2- hydroxypropoxy)phenyljbenzamide
APCI-MS: m/z 540 [MH+] iixampie 36
N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinylj]amino}-2-hydroxy-2- methylpropoxy)phenyljbenzamide
APCI-MS: m/z 508 [MH+]
Example 37 1s N-[2-(3-{[1-(4-Fluorobenzyl)-4-piperidinyljamino}-2-hydroxy-2- methylpropoxy)phenyl]benzamide
APCI-MS: m/z 492 [MH+]
Example 38
N-[2-(3-{[(3R)-1-(4-Chlorobenzyl)pyrrolidinyl]amino}-2-hydroxy-2- methyipropoxy)phenyljbenzamide
APCI-MS: m/z 494 [MH] )
Example 39 :
N-[2-(3-{[1-(4-Bromobenzyl)-4-piperidinyl]amino}-2-hydroxy-2- methylpropoxy)phenyl]benzamide
APCI-MS: m/z 554 [MH+]
Example 40
N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinyl]amino}-2-hydroxypropoxy)-4- methoxyphenyl]acetamide s :
APCI-MS: m/z 462 [MH+]
Example 41
N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinyl]amino}-2-hydroxypropoxy)-6- fluorophenyl]acetamide
APCI-MS: m/z 450 [MH+]
Example 42
N-[2-Fluoro-6-(3-{[1-(4-fluorobenzyl)-4-piperidinyljamino}-2- hydroxypropoxy)phenyl]acetamide
APCI-MS: m/z 434 [MH+]
Example 43 2-(3-{[1-(4-Chlorobenzyl)-4-piperidinyl]amino}-2-hydroxy-2-methylpropoxy)-/V- methylbenzamide
APCI-MS: m/z 446 [MH+] : Example 44
N-(2-{3-[1-(3,4-Dichlore-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}-phenyl)- benzamide
To a solution of N-(2-Oxiranylmethoxy-phenyl)-benzamide (0.2ml, 0.1M in DMSO) was added (0.2ml, 0.1M in EtOH) of 1-(3,4-Dichloro-benzyl)-piperidin-4-ylamine. The resulting mixture was heated at 75-80°C for 24hours. The ethanol was removed and the product was purified with preparative LC/MS.
APCI-MS: m/z 529[MH™]
The foiiowing Exampies 45-63 were synthesised by methods analogous to the method described in Example 44.
Example 45
N-(2-{3-[1-(3-Chloro-4-fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}- phenyl)-benzamide is APCI-MS: m/z 513[MH"]
Example 46
N-(2-{3-[1-(3,4-Difluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}-phenyl)- benzamide.
APCI-MS: m/z 496[MH"]
Example 47
N-(2-{3-[1-(3,4-Dichlore-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}-6-methyl- 2s phenyl)-acetamide
APCI-MS: m/z 481[MH"]
Example 48
N-(2-{3-[1-(4-Fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}-6-methyl- phenyl)-acetamide
APCI-MS: m/z 430[MH]
Example 49
N-(2-{3-[1-(4-Bromo-benzyl)-piperidin-4-ylamino}-2-hydroxy-2-methyl-propoxy}- phenyl)-acetamide
APCI-MS: m/z 490[M+]
Example 50
N-(2-{3-[1-(3,4-Dichloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-2-methyl-propoxy}- phenyl)-acetamide :
APCI-MS: m/z 481[MH"]
Example 51
N-(2-{3-[1-(3-Chloro-4-fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-2-methyl- propoxy}-phenyl)-acetamide
APCI-MS: m/z 464[MH"]
Example 52 2s N-(2-{3-[1-(3,4-Difluoro-benzyl)-piperidin-4-ylamino}-2-hydroxy-2-methyl-propexy}- . phenyl)-acetamide
APCI-MS: m/z 448[MH]
Example 53
2-{3-[1-(4-Bromo-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}-N-methyl- benzamide
APCI-MS: m/z 476[M’]
Example 54 2-{3-[1-(3,4-Dichloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}-N-methyl- benzaniide
APCI-MS: m/z 467[M"]
Example 55 2-{3-[1-(4-Chloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}-N-methyl- benzamide
APCI-MS: m/z 432[MH"]
Example 56 2-{3-[1-(4-Fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}-N-methyl- benzamide
APCI-MS: m/z 416]MH"]
Example 57 3,5-Dimethyl-1H-pyrrole-2-carboxylic acid (2-{3-[1-(4-bromo-benzyl)-piperidin-4- ylamino]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS: m/z 456[MH")
Example S8
3,5-Dimethyl-1H-pyrrole-2-carboxylic acid (2-{3-[1-(3-chloro-benzyl)-piperidin-4- ylamino]-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS: m/z 512[MH"]
Example 59 3,5-Dimethyl-1H-pyrrole-2-carboxylic acid (2-{3-[1-(3-fluoro-benzyl)-piperidin-4- ylamino}-2-hydroxy-propoxy}-phenyl)-amide
APCI-MS: m/z 495[MH']
Example 60
N-(2-{3-[1-(4-Bromo-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS: m/z 476[M"]
Example 61
N-(2-{3-[1-(3-Chloro-4-fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}- phenyl)-acetamide
APCI-MS: m/z 450[MH"]
Example 62 | :
N-(2-{3-[1-(3,4-Difluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}-phenyl)- . acetamide
APCI-MS: m/z 434[MH"]
Example 63
N-(2-{3-[1-(4-Fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS: m/z 416]MH"]
THP-1 Chemotaxis Assay iniroduction
The assay measured the chemotactic response elicited by MIP-1c chemokine in the human monocytic cell line THP-1. The compounds of the Examples were evaluated by their ability to depress the chemotactic response to a standard concentration of MIP-1a chemokine.
Methods 1s Culture of THP-1 cells
Cells were thawed rapidly at 37°C from frozen aliquots and resuspended in a 25 cm flask containing 5 ml of RPMI-1640 medium supplemented with Glutamax and 10% heat inactivated fetal calf serum without antibiotics (RPMI+10%HIFCS). At day 3 the medium is discarded and replaced with fresh medium.
THP-1 cells are routinely cultured in RPMI-1640 medium supplemented with 10% heat inactivated fetal calf serum and giutamax but without antibiotics. Optimal growih of the cells requires that they are passaged every 3 days and that the minimum subculture density 1s 4x10+5 cells/ml.
Chemotaxis assay .
Cells were removed from the flask and washed by centrifugation in
RPMI+10%HIFCS+glutamax. The cells were then resuspended at 2x10+7 cells/ml in fresh medium (RPMI+10%HIFCS+glutamax) to which was added calcein-AM (5 pl of stock solution to 1 ml to give a final concentration of 5x107°M). After gentle mixing the cells were incubated at 37°C in a CO, incubator for 30 minutes. The cells were then diluted to 50 ml with medium and washed twice by centrifugation at 400xg. Labelled cells were then resuspended at a cell concentration of 1x10+7 cells/ml and incubated with an equal volume of MIP-1a antagonist (10M to 10M final concentration) for 30 minutes sat 37°C in a humidified CO, incubator.
Chemotaxis was performed using Neuroprobe 96-well chemotaxis plates employing 8 pm filters (cat no. 101-8). Thirty microlitres of chemoattractant supplemented with various concentrations of antagonists or vehicle were added to the lower wells of the plate in triplicate. The filter was then carefully positioned on top and then 25ul of cells preincubated with the corresponding concentration of antagonist or vehicle were added to the surface of the filter. The plate was then incubated for 2 hours at 37°C in a humidified
CO; incubator. The cells remaining on the surface were then removed by adsorption and the whole plate was centrifuged at 2000 rpm for 10 minutes. The filter was then removed 1s and the cells that had migrated to the lower wells were quantified by the fluorescence of cell associated calcein-AM. Cell migration was then expressed in fluorescence units after subtraction of the reagent blank and values were standardized to % migration by comparing the fluorescence values with that of a known number of labelled cells. The effect of antagonists was calculated as % inhibition when the number of migrated cells were compared with vehicle.
Claims (36)
1. A compound of general formula weft vf Rr’ RS R RT ; X z' SAE R . Rs HRY “OH 0 wherein mis0,1,2or3; each R! independently represents halogen, cyano, nitro, carboxyl, hydroxyl, C3-Cg cycloalkyl, C,-Cg alkoxy, C;-Cg alkoxycarbonyl, C,-Cg haloalkyl, 10 C;-Cg haloalkoxy, -NR’R'®, C3-C cycloalkylamino, C;-Cg alkylthio, C,-Cs alkylcarbonyl, C,-Cg alkylcarbonylamino, sulphonamido, C,-Cg alkylsulphonyl, -CONR''R", -NR"’C(0)-(NH),R"*, phenyl, or C;-C alkyl optionally substituted by carboxy! or C;-Cg alkoxycarbonyl; pisOorl; Zz! represents a bond or a group (CH,), where qis 1 or2; 7? represents a bond or a group CH,, with the proviso that Zz! and 72 do not both simultaneously represent a bond; Q represents an oxygen or sulphur atom or a group CH, or NH; R® represents a group R'S ; nis0, 1 or2; each R’ independently represents a C;-Cg alkyl, C;-Cg alkoxycarbonyl, -CH,0H or carboxyl group;
RY, R’,R®and R’ each independently represent a hydrogen atom or a C;-Cg alkyl group, or RY, Rr, R® and R’ together represent a C,-C,4 alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle, or Rr’, RS and R7 each represent a hydrogen atom and R* and R® together with the carbon s atoms to which they are attached form a 5- to 6-membered saturated carbocycle; RS represents a hydrogen atom, a C,-Cg alkyl group or is linked to R* as defined above;
R® and R'® each independently represent a hydrogen atom or a C;-Cg alkyl group, or R’ and R"? together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
R'! and R'? each independently represent a hydrogen atom or a C;-Cg alkyl group optionally substituted by C;-C¢ alkoxycarbonyl; rR" represents a hydrogen atom or a C;-Cg4 alkyl group;
rR" represents a hydrogen atom, or a C;-Cg alkyl group optionally substituted by carboxyl, C{-Cg alkoxy or C-Cg alkoxycarbonyl;
rR" represents carboxyl, C,-Cq alkoxy, C;-Cg alkylcarbonyl, C;-Cg4 alkoxycarbonyl, C-Cg alkoxycarbonylC;-Cg alkyl or a group NR'RS, -NHSO,CHj3;, -C(O)NR''R"®, -NHC(O)NR''R'®, -0C(O)NR''R'®, -0CH,C(O)NR'R'®, NHC(0)OR" or _NHC(O)R?,
» tis 0, 1,2 or 3; :
each R'® independently represents halogen, cyano, nitro, carboxyl, hydroxyl,
C3-Cg cycloalkyl, C;-Cg alkoxy, C;-Cg4 alkoxycarbonyl, C;-C¢ haloalkyl,
C,-Cg haloalkoxy, NR?'R%, C;-Cg cycloalkylamino, C{-Cg alkylthio,
C,-Cg alkylcarbonyl, C;-Cg4 alkylcarbonylamino, sulphonamido, C;-Cg alkylsulphonyl, 2» -C(ONR®R*, -NR*™C(0)(NH),R*, phenyl, or C,-Cg alkyl optionally substituted by carboxyl or C-Cg¢ alkoxycarbonyl;
R'” and R'® each independently represent a hydrogen atom, or a C,-C alkyl group optionally substituted by carboxyl or C;-C¢ alkoxycarbonyl, or R' and R'® together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocycle;
Rr" represents a hydrogen atom, or a C;-Cg alkyl group optionally substituted by carboxyl or C;-C¢ alkoxycarbonyl; R* represents a group C,-Cg alkyl, C,-Cq alkenyl, C5-C¢ cycloalkyl, adamantyl, Cs-Cg cycloalkenyl, phenyl or a saturated or unsaturated 5- to 10-membered heterocyclic s ring system comprising at least one heteroatom selected from nitrogen, oxygen and sulphur, each of which may be optionally substituted by one or more substituents independently selected from nitro, hydroxyl, oxo, halogen, carboxyl, C;-Cg alkyl, C,-Cq alkoxy, C;-C¢ alkylthio, C,-Cq alkylcarbonyl, C-Cq alkoxycarbonyl, phenyl and _NHC(0)-R”; R*! and R** each independently represent a hydrogen atom or a C-Cg alkyl! group, or R*! and R® together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle; R? and R* each independently represent a hydrogen atom or a C;-Cg alkyl group optionally substituted by C,-C alkoxycarbonyl; visOorl; R% represents a hydrogen atom or a C,-Cy alkyl group: R* represents a hydrogen atom, or a C,-Cq alkyl group optionally substituted by carboxyl, C,-Cg¢ alkoxy or C-Cg¢ alkoxycarbonyl; and Rr” represents a C-Cg alkyl, amino (-NH;) or phenyl group; or a pharmaceutically acceptable salt or solvate thereof.
2. A compound according to claim 1, wherein m is i or 2.
3. A compound according to claim 2, wherein each R' represents a halogen atom.
4. A compound according to any one of claims 1 to 3, wherein Q represents an oxygen atom.
5. A compound according to any one of claims 1 to 4, wherein rR" represents a group 0 -NHC(O)R®.
6. A compound according to claim 5, wherein, in R%, the saturated or unsaturated 5- to 10-membered heterocyclic ring system comprising at least one heteroatom selected from nitrogen, oxygen and sulphur, is pyrrolidinyl, piperidinyl, pyrazolyl, thiazolidiny], thienyl, isoxazolyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, quinolinyl, benzimidazolyl, triazolyl, tetrazolyl or pyridinyl.
7. A compound according to any one of claims 1 to 6, wherein each R'® independently represents halogen, cyano, C;-C,4 alkoxy, C,-C, alkoxycarbonyl, C,-C, haloalkyl, to C,-C4 alkylcarbonyl, phenyl or C;-C, alkyl.
8. A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as defined in claim 1 being selected from: N-[2-(3-{[1-(3,4-dichlorobenzylpiperidinylJaminohydroxypropoxy)phenyljacetamide, (5 N-[5-chloro-2-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinyljamino}-2- hydroxypropoxy)phenyl]acetamide, N-[2-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinylJamino } -2-hydroxypropoxy)-5- methylphenyljacetamide, N-[4-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinyl]amino } -2-hydroxypropoxy)[1,1'- biphenyl]-3-yllacetamide, N-[3-acetyl-2-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinyl]amino} -2-hydroxypropoxy)- 5-methylphenyl]acetamide, N-[2-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinyl]amino} -2-hydroxypropoxy)-4- fluorophenyl]acetamide, N-[2-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinylJamino}-2-hydroxypropoxy)-5- fluorophenyljacetamide, N-[2-(3-{[1-(3,4-dichlorobenzyl)-4-piperidinylJamino} -2-hydroxypropoxy)-5- cyanophenyl]acetamide, N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinylJamino} -2-hydroxypropoxy)phenyl]- acetamide,
N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl]amin0 } -hydroxypropoxy)phenyl]- 1sobutyramide, N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl]Jamino}-2-hydroxypropoxy)phenyl]-2-2- dimethyl-propiomanide, N-{5-chloro-2-(3-{[1-(4-chlorobenzyl)-4-piperidinyi]amino} -2- hydroxypropoxy)phenyl]acetamide, N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinylJamino} -2-hydroxypropoxy)-5- methyiphenyijacetamde, N-[2-(3-{[1-(4-chlorobenzy!)-4-piperidinylJamino} -2-hydroxypropoxy)-4- methylphenyl]acetamide, N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl amino} -2-hydroxypropoxy)-4- fluorophenyllacetamide, N-[2-(3-{[1-(4-chlorobenzyl)-4-piperidinyl]amino} -2-hydroxypropoxy)-5- cvanaphenyllacetamide.
N-(2-{[(2S)-3-({-[(4-Chlorophenyl)methyl |-4-piperidinyl }amino)-2- hydroxypropylloxy}phenylacetamide bi(trifluoroacetate), N-(2-{(2R)-3-[1-(4-Chloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-2-methyl- propoxy}-phenyl)-acetamide, N-(2-{[3-({ 1-[(4-Chlorophenyl)methyl]-4-piperidinyl} amino)-2-hydroxy-2- methylpropyl]oxy}phenyl)acetamide, N-(2-{(25)-3-[1-(4-Chloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-2-methyl- propoxy }-phenyl)-acetamide, N-{2-[((2S)-3-{[1-(4-Fluorobenzyl)-4-piperidinyl Jamino } -2- hydroxypropyl)oxy]phenyl} acetamide, N-{2-[((2S)-3-{[1-(4-Chlorobenzyl)-4-piperidinyl]amino}-2-hydroxypropyl)oxy]-4- fluorophenyl}acetamide, N-{4-fluoro-2-[((2S)-3-{[1-(4-fluorobenzyl)-4-piperidinyl]amino}-2- hydroxypropyl)oxy]phenyl}acetamide, N-{2-[((2S)-3-{[(35)-1-(4-Chlorobenzyl)pyrrolidinylJamino} -2-hydroxypropyl)oxyl- 4-fluorophenyl}acetamide,
N-{2-[((25)-3-{[(3R)-1-(4-Chlorobenzyl)pyrrolidinylJamino} 2-hydroxypropyl)oxy]- 4-fluorophenyl} acetamide, N-[2-(3- {[1-(4-Fluorobenzyl)-4-piperidinylJamino} -2-hydroxy-2- methylpropoxy)phenyljacetamide, N-[2~(3- {[1-(4-Chlorobenzyl)-4-piperidinylJamino} -2-hydroxy-2-methylpropoxy)-4- fluorophenyl]acetamide, N-[4-Fluoro-2-(3- {[1-(4-fluorobenzyl)-4-piperidinyl]amino} -2-hydroxy-2- methylpropoxy)phenyl]acetamide, N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinylJamino}-2-hydroxypropoxy)-4- methylphenyl]acetamide, N-[2-(3-{[1-(4-Fluorobenzyl)-4-piperidinylJamino}-2-hydroxypropoxy)-4- methylphenyl]acetamide, N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinylJamino} -2- hydroxypropoxy)phenyl]benzamide, N-[2-(3-{[1-(4-Fluorobenzyl)-4-piperidinylJamino}-2- hydroxypropoxy)phenyl]benzamide, N-[2-(3-{[(3S)-1-(4-Chlorobenzyl)pyrrolidinylJamino}-2- hydroxypropoxy)phenyl]benzamide, N-[2-(3-{[(3R)-1-(4-Chlorobenzyl)pyrrolidinyl]Jamino} -2- hydroxypropoxy)phenyl]benzamide, N-[2-(3-{[1-(4-Bromobenzyl)-4-piperidinyl Jamino}-2- hydroxypropoxy)phenyl]benzamide, N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinyl]amino}-2-hydroxy-2- methylpropoxy)phenyl]benzamide, N-[2-(3-{[1 -(4-Fluorobenzy1)-4-piperidinyl] amino}-2-hydroxy-2- methylpropoxy)phenyl]benzamide, N-[2-(3-{[(3R)-1-(4-Chlorobenzyl)pyrrolidinyl ]amino }-2-hydroxy-2- methylpropoxy)phenyl]benzamide, N-[2-(3- {[1-(4-Bromobenzyl)-4-piperidinylJamino}-2-hydroxy-2- methylpropoxy)phenyl]benzamide,
N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinylJamino -2-hydroxypropoxy)-4- methoxyphenyl]acetamide, N-[2-(3-{[1-(4-Chlorobenzyl)-4-piperidinyl]amino } -2-hydroxypropoxy)-6- fluorophenyl]acetamide, N-[2-Fluoro-6-(3-{[1-(4-fluorobenzyl)-4-piperidinyllamino} -2- hydroxypropoxy)phenyl]acetamide, 2-(3-{[1-(4-Chlorobenzyl)-4-piperidinyl]amino}-2-hydroxy-2-methylpropoxy)-N- methyibenzamide, N-(2-{3-[1-(3,4-Dichloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy} -phenyl)- benzamide, N-(2-{3-[1-(3-Chloro-4-fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}- phenyl)-benzamide, : N-(2-{3-[1-(3,4-Difluoro-benzyl)-piperidin-4-ylamino}-2-hydroxy-propoxy} -pheny})- henzamide. 1s N-(2-{3-[1-(3,4-Dichloro-benzyl)-piperidin-4-ylamino J-2-hydroxy-propoxy } -6- methyl-phenyl)-acctamide, N-(2- {3-[1-(4-Fluoro-benzyl)-piperidin-4-ylamino}-2-hydroxy-propoxy} -6-methyl- phenyl)-acetamide, N-(2-{3-[1-(4-Bromo-benzyl)-piperidin-4-ylamino]-2-hydroxy-2-methyl-propoxy } - phenyl)-acetamide, N-(2-{3-[1-(3,4-Dichloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-2-methyl- propoxy }-phenyl)-acetamide, N-(2- {3-[1-(3-Chloro-4-fluoro-benzyl)-piperidin-4-ylamino}-2-hydroxy-2-methyl- propoxy }-phenyl)-acetamide, N-(2-{3-[1-(3,4-Difluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-2-methyl- propoxy }-phenyl)-acetamide, 2-{3-[1-(4-Bromo-benzyl)-piperidin-4-ylamino}-2-hydroxy-propoxy} -N-methyl- benzamide, 2-{3-[1-(3,4-Dichloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy } -N-methyl- benzamide,
2-{3-[1-(4-Chloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy} -N-methy]l- benzamide, 2-{3-[1-(4-Fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy} -N-methyl- benzamide, 3,5-Dimethyl-1H-pyrrole-2-carboxylic acid (2-{3-[1-(4-bromo-benzyl)-piperidin-4- ylamino]-2-hydroxy-propoxy}-phenyl)-amide, 3,5-Dimethyl-1H-pyrrole-2-carboxylic acid (2-{3-[1-(3-chloro-benzyl)-piperidin-4- ylamino]-2-hydroxy-propoxy}-phenyl)-amide, 3,5-Dimethyl-1H-pyrrole-2-carboxylic acid (2-{3-[1-(3-fluoro-benzyl)-piperidin-4- ylamino]-2-hydroxy-propoxy}-phenyl)-amide, N-(2-{3-[1-(4-Bromo-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy } -phenyl)- acetamide, N-(2-{3-[1-(3-Chloro-4-fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy} - phenyl)-acetamide, N-(2-{3-[1-(3,4-Difluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy } -phenyl)- acetamide, and N-(2-{3-[1-(4-Fluoro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy} -phenyl)- acetamide.
9. A process for the preparation of a compound of formula (I) as defined in claim 1 which comprises, (a) reacting a compound of general formula R' cS J 7 1 RY), Z NH, ay wherein m, n, z!, 72, R! and R? are as defined in formula (D), with a compound of general formula oR 4 >< ~_ Rr? 7 (IID
. 2 4 55 6 7 8 . wherein Q,R™, R",R", R", R" and R" are as defined in formula (I); or (b) reacting a compound of general formula 5 I i rR? RS (R Ji I 1 | RR ZZ 1
NN . PS ee (Rn R av)
. 1 52 51 53 54 5 6 7 8 . . whereinm,n,Z ,Z",R",R",R,R",R",R and R" are as defined in formula (I), with a compound of general formula L'-Q-R* (VW) wherein L! represents a hydrogen atom or a leaving group and Q and R” arc as defined in formula (I); or (c) reacting a compound of general formula ZN2 ~~ N™ ~z LY L = NF ~ Zz" So (R) " (VD wherein m, n, z} 72, R! and R? are as defined in formula (1), with a compound of general formula HOR’ q HN Nn? .
wherein Q, Rr, RY R>, RS, R” and R® are as defined in formula (I); and optionally after (a), (b) or (c) converting the compound of formula (I) to a further compound of formula (I) and/or forming a pharmaceutically acceptable salt or solvate of the compound of formula (I).
10. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
11. A process for the preparation of a pharmaceutical composition as claimed in claim 10 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 with a pharmaceutically acceptable adjuvant, diluent or carrier.
12. A compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 for use in therapy.
13. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in therapy.
14. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.
15. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating rheumatoid arthritis.
16. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating chronic obstructive pulmonary disease.
17. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating asthma.
18. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use In treating multiple sclerosis.
19. A method of treating an inflammatory disease in a patient suffering from, or at risk of. 1s said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8.
20. A method of treating an airways disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 io 8.
60 PCT/SE01/01377
16. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating chronic obstructive pulmonary disease.
17. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating asthma.
18. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating multiple sclerosis.
19. A method of preventing an inflammatory disease in a subject at risk of said disease, which comprises administering to the subject an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8.
20. A method of preventing an airways disease in a subject at risk of said disease, which comprises administering to the subject an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8. :
21. A substance or composition for use in a method for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial, said substance or composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claim 1 to 8, and said method comprising administering said substance or composition.
22. A substance or composition for use in a method for treating rheumatoid arthritis, said substance or composition comprising a compound of formula (I), or a AMENDED SHEET f
61 PCT/SE01/01377 pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8, and said method comprising administering said substance or composition.
23. A substance or composition for use in a method for treating chronic obstructive pulmonary disease, said substance or composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8, and said method comprising administering said substance or composition.
24. A substance or composition for use in a method for treating asthma, said substance or composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8, and said method comprising administering said substance or composition.
25. A substance or composition for use in a method for treating multiple sclerosis, said substance or composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8, and said method comprising administering said substance or composition.
26. A substance or composition for use in a method of treating inflammatory disease in a subject suffering from or at risk of, said disease,said substance or composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate : thereof, as claimed in any one of claims 1 to 8, and said method comprising administering a therapeutically effective amount of said substance or composition to the subject.
27. A substance or composition for use in a method of treating an airways disease in a subject suffering from, or at risk of, said disease, said substance or composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8, and said method comprising administering a therapeutically effective amount of said substance or composition to the AMENDED SHEET f
] 62 PCT/SE01/01377 subject.
28. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8, in the manufacture of a preparation for treating an inflammatory disease in a subject suffering from, or at risk of said disease.
29. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8, in the manufacture of a preparation for treating an airways disease in a subject suffering from, or at risk of, said disease.
30. A compound according to claim 1, substantially as herein described and illustrated.
31. A process according to claim 9, or claim 11, substantially as herein described and illustrated.
32. A composition according to claim 10, substantially as herein described and illustrated.
33. A substance or composition for use in a method of treatment according to claim 12, or any of claims 21 to 27, substantially as herein described and illustrated.
34. Use according to any of claims 13 to 18, or 28, or 29, substantially as herein described and illustrated.
35. A method according to claim 19, or claim 20, substantially as herein described and illustrated.
36. A new compound; a new process for preparing a compound; a new process for preparing a composition; a new composition; a substance or composition for a new use in a method of treatment; a new use of a compound of formula (I), or a pharmaceutically AMENDED SHEET ¢
: | 63 PCT/SE01/01377 acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8; or a new non- therapeutic method of treatment, substantially as herein described.
AMENDED SHEET !
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0002331A SE0002331D0 (en) | 2000-06-20 | 2000-06-20 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200209904B true ZA200209904B (en) | 2004-03-05 |
Family
ID=20280190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200209904A ZA200209904B (en) | 2000-06-20 | 2002-12-05 | Novel compounds. |
Country Status (2)
Country | Link |
---|---|
SE (1) | SE0002331D0 (en) |
ZA (1) | ZA200209904B (en) |
-
2000
- 2000-06-20 SE SE0002331A patent/SE0002331D0/en unknown
-
2002
- 2002-12-05 ZA ZA200209904A patent/ZA200209904B/en unknown
Also Published As
Publication number | Publication date |
---|---|
SE0002331D0 (en) | 2000-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6911458B2 (en) | Compounds | |
AU2001274763A1 (en) | Novel compounds | |
EP1263725B1 (en) | Novel compounds | |
US7388020B2 (en) | Benzimidazol derivatives modulate chemokine receptors | |
EP1372651B1 (en) | Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity | |
US7186718B2 (en) | Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity | |
EP1299356B1 (en) | Novel compounds | |
EP1421070B1 (en) | New piperidinyl derivates as modulators of chemokine receptor activity | |
US7005439B2 (en) | Compounds | |
ZA200209904B (en) | Novel compounds. | |
AU2001274764B2 (en) | Novel compounds | |
ZA200209906B (en) | Novel compounds. | |
AU2001274764A1 (en) | Novel compounds | |
AU2002243154A1 (en) | Novel amides, preparation and therapeutic use as modulators of CCR-receptor activity |